

(43) International Publication Date
8 December 2016 (08.12.2016)

(51) International Patent Classification:

C07D 207/277 (2006.01) *C07D 409/06* (2006.01)
C07D 401/06 (2006.01) *C07D 413/06* (2006.01)
C07D 403/06 (2006.01) *C07D 417/06* (2006.01)
C07D 405/06 (2006.01) *C07D 471/04* (2006.01)

Plaza 721/2340, 974 Centre Road, PO Box 2915 Wilmington, Delaware 19805 (US).

(21) International Application Number:

PCT/US2016/033231

(22) International Filing Date:

19 May 2016 (19.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/168,360 29 May 2015 (29.05.2015) US

(71) Applicant: **E I DU PONT DE NEMOURS AND COMPANY** [US/US]; Chestnut Run Plaza, 974 Centre Road, P.O. Box 2915, Wilmington, Delaware 19805 (US).(72) Inventors: **CAMPBELL, Matthew James**; 791 Joseph Biggs Highway, Rising Sun, Maryland 21911 (US). **SATTERFIELD, Andrew Duncan**; 12 Raphael Road, Hockessin, Delaware 19707 (US).(74) Agent: **COATS, Reed A.**; E. I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED CYCLIC AMIDES AS HERBICIDES

(57) Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, *N* oxides, and salts thereof, wherein R^1 , R^4 , R^5 , R^6 , J , Q^1 , Q^2 , A , Y^1 , and Y^2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.



TITLE
 SUBSTITUTED CYCLIC AMIDES AS HERBICIDES

FIELD OF THE INVENTION


This invention relates to certain substituted cyclic amides, their *N*-oxides and salts, and 5 compositions and methods of their use for controlling undesirable vegetation.

BACKGROUND OF THE INVENTION

The control of undesired vegetation is extremely important in achieving high crop efficiency. Achievement of selective control of the growth of weeds especially in such useful crops as rice, soybean, sugar beet, maize, potato, wheat, barley, tomato and plantation 10 crops, among others, is very desirable. Unchecked weed growth in such useful crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. The control of undesired vegetation in noncrop areas is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have 15 different sites of action.

SUMMARY OF THE INVENTION

This invention is directed to compounds of Formula 1 (including all stereoisomers), *N*-oxides and salts thereof, agricultural compositions containing them and their use as herbicides:



20

wherein

A is a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3 atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, wherein up to 2 carbon members are independently selected from C(=O) and C(=S) and the sulfur atom member is selected from S(=O)_u(=NR⁸)_v; the said chain optionally substituted with up to 5 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms;

25

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷; or a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic 30 bicyclic ring system, each ring or ring system containing ring members selected

from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

5 Q² is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 10 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom 15 ring members;

Y¹ and Y² are each independently O, S or NR¹²;

20 J is -CR²R³-; or -CR²R³-CR^{2a}R^{3a}- wherein the -CR²R³- moiety is directly connected to N;

25 R¹ is H, hydroxy, amino, cyano, formyl, C₃-C₈ alkylcarbonylalkyl, -C(C₁-C₄ alkyl)=N-O(C₁-C₄ alkyl), -C(O)NH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₂-C₈ alkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ haloalkenylalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₅-C₁₀ cycloalkylcarbonylalkyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkoxycarbonyl, C₄-C₁₀ cycloalkoxycarbonyl, C₂-C₈ alkylaminoalkyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₄-C₁₀ cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₃-C₈ cycloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl, C₃-C₁₀ trialkylsilyl; or 30 arylcarbonyl, arylalkenylalkyl, arylcarbonylalkyl or -CPh=N-O(C₁-C₄ alkyl), each optionally substituted on ring members with up to 5 substituents independently selected from R¹³; or G¹;

R² and R³ are each independently H, halogen, hydroxy, C₁–C₄ alkyl, C₁–C₄ haloalkyl or C₁–C₄ alkoxy; or

R² and R³ are taken together with the carbon atom to which they are bonded to form a C₃–C₇ cycloalkyl ring;

5 R^{2a} and R^{3a} are each independently H, halogen or C₁–C₄ alkyl; or

R^{2a} and R^{3a} are taken together with the carbon atom to which they are bonded to form a C₃–C₇ cycloalkyl ring;

each R⁴ is independently H, halogen, hydroxy, C₁–C₄ alkoxy or C₁–C₄ alkyl;

each R⁵ is independently H, halogen, hydroxy, C₁–C₄ alkoxy, cyano or C₁–C₄ alkyl;

10 R⁶ is H, hydroxy, amino, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀

15 cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ 20 dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹;

each R⁷ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈

25 haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ 30 haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄

alkylcarbonylamino, -SF₅, -SCN, C₄–C₁₀ cycloalkylalkoxy, C₄–C₁₀ cycloalkylalkyl, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkoxyalkoxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ 35 haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₂–C₈

alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or G²; or
5 R¹⁷ON=CR^{17a}–, (R¹⁸)₂C=NO–, (R¹⁹)₂NN=CR^{17a}–, (R¹⁸)₂C=NNR^{20a}–, R²⁰N=CR^{17a}–, (R¹⁸)₂C=N–, R¹⁷ON=CR^{17a}C(R^{23b})₂– or (R¹⁸)₂C=NOC(R^{24a})₂–, wherein the free bond projecting to the right indicates the connecting point to Q¹; or

two adjacent R⁷ are taken together along with the carbon atoms to which they are

10 bonded to form a C₃–C₇ cycloalkyl ring;

each R¹⁰ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyoxy, C₃–C₈ haloalkynyoxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₄–C₁₀ cycloalkylalkoxy, C₄–C₁₀ cycloalkylalkyl, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or G²; or

35 R¹⁷ON=CR^{17a}–, (R¹⁸)₂C=NO–, (R¹⁹)₂NN=CR^{17a}–, (R¹⁸)₂C=NNR^{20a}–, R²⁰N=CR^{17a}–, (R¹⁸)₂C=N–, R¹⁷ON=CR^{17a}C(R^{23b})₂– or (R¹⁸)₂C=NOC(R^{24a})₂–, wherein the free bond projecting to the right indicates the connecting point to Q²; or

two adjacent R¹⁰ are taken together along with the carbon atoms to which they are bonded to form a C₃–C₇ cycloalkyl ring;

each R⁸ is independently H, cyano, C₂–C₃ alkylcarbonyl or C₂–C₃ haloalkylcarbonyl;
each R⁹ and R¹¹ is independently cyano, C₁–C₃ alkyl, C₂–C₃ alkenyl, C₂–C₃ alkynyl,
C₃–C₆ cycloalkyl, C₂–C₃ alkoxyalkyl, C₁–C₃ alkoxy, C₂–C₃ alkylcarbonyl,
C₂–C₃ alkoxy carbonyl, C₂–C₃ alkylaminoalkyl or C₃–C₄ dialkylaminoalkyl;

5 each R¹² is independently H, cyano, C₁–C₄ alkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy,
C₁–C₄ haloalkoxy, -(C=O)CH₃ or -(C=O)CF₃;

each G¹ is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl,
phenylcarbonyl (i.e. benzoyl), phenoxy, phenylethynyl, phenylsulfonyl,
phenylcarbonylalkyl, 2-, 3- or 4-pyridinyloxy or a 5- or 6-membered
10 heteroaromatic ring, each optionally substituted on ring members with up to 5
substituents independently selected from R¹³;

each G² is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl,
phenylcarbonyl (i.e. benzoyl), phenylcarbonylalkyl, phenoxy, phenylethynyl,
15 phenylsulfonyl, 2-, 3- or 4-pyridinyloxy or a 5- or 6-membered heteroaromatic
ring, each optionally substituted on ring members with up to 5 substituents
independently selected from R¹⁴;

each R¹³ and R¹⁴ is independently halogen, cyano, hydroxy, amino, nitro, -CHO,
-C(=O)OH, -C(=O)NH₂, -SO₂NH₂, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆
20 alkenyl, C₂–C₆ alkynyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₂–C₈
alkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₅–C₁₂
cycloalkylalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀
25 dialkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ haloalkoxy, C₂–C₈
alkylcarbonyloxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₁–C₆ alkylsulfinyl,
C₁–C₆ haloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₁–C₆
30 alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl, C₁–C₆
alkylamino, C₂–C₈ dialkylamino, C₂–C₈ alkylcarbonylamino, C₁–C₆
alkylsulfonylamino, phenyl, pyridinyl or thienyl;

each R¹⁵ is independently halogen, cyano, hydroxy, C₁–C₄ alkyl, C₁–C₄ haloalkyl,
C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl,
35 C₂–C₄ alkoxy carbonyl, C₃–C₆ cycloalkyl or C₄–C₈ cycloalkylalkyl; or
two R¹⁵ are taken together with the carbon atom(s) to which they are bonded to form a
C₃–C₇ cycloalkyl ring;

each R¹⁶ is independently cyano, C₁–C₄ alkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₂–C₄
alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl;

35 each R¹⁷ is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl,
C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈
haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈
alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀

cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹;

each R^{17a} is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio or C₃–C₁₀ trialkylsilyl; or G¹;

alkylsulfonylalkyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio or C₃–C₁₀ trialkylsilyl; or G¹;

each R¹⁸ is independently H, hydroxy, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈

15 alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈
haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈
haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl,
C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy,
C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆

20 alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆
alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆
alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹;

each R¹⁹ is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈

25 haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈
alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀
cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀
cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀

alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹; each R²⁰ is independently H, hydroxy, amino, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylsilyl, C₁–C₆ haloalkyl, C₃–C₈ alkenyl, C₃–C₈ alkynyl, C₁–C₆

35 cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ arkenyl, C₃–C₆ arkylyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbenyl, C₂–C₈

alkylsulfonylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl

C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹;

5 each R^{20a} is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₆ alkoxy or C₃–C₁₀ trialkylsilyl; or G¹;

10 each R^{23b} is independently H, halogen, cyano, hydroxy, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl;

15 each R^{24a} is independently H, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl; and

each u and v are independently 0, 1 or 2 in each instance of S(=O)_u(=NR⁸)_v, provided that the sum of u and v is 0, 1 or 2;

provided when A is S and Q¹ is unsubstituted phenyl, Q² is other than unsubstituted phenyl.

20 More particularly, this invention pertains to a compound of Formula 1 (including all stereoisomers), an N-oxide or a salt thereof. This invention also relates to a herbicidal composition comprising a compound of the invention (i.e. in a herbicidally effective amount) and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents. This invention further relates to a method for controlling the growth of 25 undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a compound of the invention (e.g., as a composition described herein).

This invention also includes a herbicidal mixture comprising (a) a compound selected from Formula 1, N-oxides and salts thereof, and (b) at least one additional active ingredient 30 selected from (b1) through (b16); and salts of compounds of (b1) through (b16), as described below.

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains”, “containing,” “characterized by” or any other variation thereof, are 35 intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other

elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.

The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase “consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.

Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms “consisting essentially of” or “consisting of.”

Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to herein, the term “seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed.

As referred to herein, the term “broadleaf” used either alone or in words such as “broadleaf weed” means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons.

In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, *n*-propyl, *i*-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. “Alkynyl” includes straight-chain or branched alkynes

such as ethynyl, 1-propynyl, 2-propynyl, and the different butenyl, pentenyl and hexynyl isomers. The term “trialkylsilyl” means three alkyl groups attached through silicon, with each alkyl being the same or different.

“Alkoxy” includes, for example, methoxy, ethoxy, *n*-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH_3OCH_2- , $\text{CH}_3\text{OCH}_2\text{CH}_2-$, $\text{CH}_3\text{CH}_2\text{OCH}_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{OCH}_2-$ and $\text{CH}_3\text{CH}_2\text{OCH}_2\text{CH}_2-$. “Alkoxyalkoxy” denotes alkoxy substitution on alkoxy. “Alkoxyalkoxyalkyl” denotes alkoxy substitution on the alkoxy moiety of alkoxyalkyl moiety. Examples of “alkoxyalkoxyalkyl” include $\text{CH}_3\text{OCH}_2\text{OCH}_2-$, $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_3)\text{CHOCH}_2-$ and $(\text{CH}_3\text{O})_2\text{CHOCH}_2-$. “Alkenyloxy” includes straight-chain or branched alkenyloxy moieties. Examples of “alkenyloxy” include $\text{H}_2\text{C}=\text{CHCH}_2\text{O}-$, $(\text{CH}_3)_2\text{C}=\text{CHCH}_2\text{O}-$, $(\text{CH}_3)\text{CH}=\text{CHCH}_2\text{O}-$, $(\text{CH}_3)\text{CH}=\text{C}(\text{CH}_3)\text{CH}_2\text{O}-$ and $\text{CH}_2=\text{CHCH}_2\text{CH}_2\text{O}-$. “Alkynyloxy” includes straight-chain or branched alkynyloxy moieties. Examples of “alkynyloxy” include $\text{HC}\equiv\text{CCH}_2\text{O}-$, $\text{CH}_3\text{C}\equiv\text{CCH}_2\text{O}-$ and $\text{CH}_3\text{C}\equiv\text{CCH}_2\text{CH}_2\text{O}-$. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include $\text{CH}_3\text{S}(\text{O})-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})-$, $(\text{CH}_3)_2\text{CHS}(\text{O})-$ and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of “alkylsulfonyl” include $\text{CH}_3\text{S}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2-$, $(\text{CH}_3)_2\text{CHS}(\text{O})_2-$, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. Examples of “alkylsulfonylamino” include $\text{CH}_3\text{S}(\text{O})_2\text{NH}-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2\text{NH}-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{NH}-$, $(\text{CH}_3)_2\text{CHS}(\text{O})_2\text{NH}-$, and the different butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino isomers. Examples of “alkylaminosulfonyl” include $\text{CH}_3\text{NHS}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{NHS}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{NHS}(\text{O})_2-$, $(\text{CH}_3)_2\text{CHNHS}(\text{O})_2-$, and the different butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino isomers. Examples of “alkylsulfonyloxy” include $\text{CH}_3\text{S}(\text{O})_2\text{O}-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2\text{O}-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{O}-$, $(\text{CH}_3)_2\text{CHS}(\text{O})_2\text{O}-$, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers. “Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of “alkylthioalkyl” include CH_3SCH_2- , $\text{CH}_3\text{SCH}_2\text{CH}_2-$, $\text{CH}_3\text{CH}_2\text{SCH}_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2\text{SCH}_2-$ and $\text{CH}_3\text{CH}_2\text{SCH}_2\text{CH}_2-$. “Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH_2- , $\text{NCCH}_2\text{CH}_2-$ and $\text{CH}_3\text{CH}(\text{CN})\text{CH}_2-$. “Cyanoalkoxy” denotes an alkoxy group substituted with one cyano group. Examples of “cyanoalkoxy” include $\text{NCCH}_2\text{O}-$, $\text{NCCH}_2\text{CH}_2\text{O}-$ and $\text{CH}_3\text{CH}(\text{CN})\text{CH}_2\text{O}-$. “Nitroalkenyl” denotes an alkenyl group substituted with one nitro group. Examples of “nitroalkenyl” include $\text{O}_2\text{NCH}=\text{CH}-$, $\text{O}_2\text{NCH}_2\text{CH}=\text{CH}-$ and $\text{CH}_2=\text{CH}(\text{NO}_2)\text{CH}_2-$. “nitroalkyl” denotes an alkyl group substituted with one nitro group. Examples of “nitroalkyl” include O_2NCH_2- , $\text{O}_2\text{NCH}_2\text{CH}_2-$ and

$\text{CH}_3\text{CH}_2\text{CH}(\text{NO}_2)\text{-}$. “Alkylsulfinylalkyl” denotes alkylsulfinyl substitution on alkyl. Examples of “alkylsulfinylalkyl” include $\text{CH}_3\text{S}(\text{=O})\text{CH}_2\text{-}$, $\text{CH}_3\text{S}(\text{=O})\text{CH}_2\text{CH}_2\text{-}$, $\text{CH}_3\text{CH}_2\text{S}(\text{=O})\text{CH}_2\text{-}$ and $\text{CH}_3\text{CH}_2\text{S}(\text{=O})\text{CH}_2\text{CH}_2\text{-}$. “Alkylsulfonylalkyl” denotes alkylsulfonyl substitution on alkyl. Examples of “alkylsulfonylalkyl” include $\text{CH}_3\text{S}(\text{=O})_2\text{CH}_2\text{-}$, $\text{CH}_3\text{S}(\text{=O})_2\text{CH}_2\text{CH}_2\text{-}$, $\text{CH}_3\text{CH}_2\text{S}(\text{=O})_2\text{CH}_2\text{-}$ and $\text{CH}_3\text{CH}_2\text{S}(\text{=O})_2\text{CH}_2\text{CH}_2\text{-}$. “Cyloalkylthio” denotes a cycloalkyl group bonded through sulfur. Examples of “cycloalkylthio” include $c\text{-PrS-}$, $c\text{-BuS-}$ and $c\text{-HexS-}$. “Cycloalkysulfinyl” and “cycloalkylsulfonyl” are defined analogously, “Alkylamino”, “dialkylamino”, and the like, are defined analogously to the above examples. Examples of “alkylaminoalkyl” include $\text{CH}_3\text{NHCH}_2\text{-}$, $(\text{CH}_3)_2\text{CHNHCH}_2\text{-}$ and $\text{CH}_3\text{NHCH}(\text{CH}_3)\text{-}$. Examples of “alkylaminocarbonyl” include $\text{CH}_3\text{NHC(O)-}$, $(\text{CH}_3)_2\text{CHNHC(O)-}$ and $\text{CH}_3\text{CH}_2\text{NHC(O)-}$. Examples of “dialkylaminoalkyl” include $(\text{CH}_3)_2\text{NCH}_2\text{-}$, $(\text{CH}_3)_2\text{NC(CH}_3\text{)H-}$ and $(\text{CH}_3)(\text{CH}_3)\text{NCH}_2\text{-}$. Examples of “alkylaminocarbonyl” include $\text{CH}_3\text{NC(O)-}$ and $\text{CH}_3\text{CH}_2\text{NC(O)-}$. Examples of “dialkylaminocarbonyl” include $(\text{CH}_3)_2\text{NC(O)-}$. Examples of “dialkylaminosulfonyl” include $(\text{CH}_3)_2\text{NS(O)}_2\text{-}$.

“Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, *i*-propylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. The term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. The term “cycloalkoxy” denotes cycloalkyl linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy. “Cycloalkylalkoxycarbonyl” denotes cycloalkyl substitution on an alkoxy carbonyl moiety. Examples of “cycloalkylalkoxycarbonyl” include $c\text{-PrCH}_2\text{OC(O)-}$, $c\text{-BuCH}_2\text{OC(O)-}$ and $c\text{-HexCH}_2\text{OC(O)-}$. “Cycloalkoxycarbonyl” denotes cycloalkoxy substitution on a carbonyl moiety. Examples of “cycloalkoxycarbonyl” include cyclopropoxycarbonyl, cyclopentoxycarbonyl, and other moieties bonded to straight-chain or branched alkyl groups. “Cycloalkylalkoxy” denotes cycloalkylalkyl linked through an oxygen atom attached to the alkyl chain. Examples of “cycloalkylalkoxy” include cyclopropylmethoxy, cyclopentylethoxy, and other cycloalkyl moieties bonded to straight-chain or branched alkoxy groups.

The term “halogen”, either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include $\text{F}_3\text{C-}$, $\text{ClCH}_2\text{-}$, $\text{CF}_3\text{CH}_2\text{-}$ and $\text{CF}_3\text{CCl}_2\text{-}$. The terms “halocycloalkyl”, “haloalkoxy”, “haloalkoxylalkyl”, “haloalkylthio”,

“haloalkylsulfinyl”, “haloalkylsulfonyl”, “haloalkylsulfonyloxy” “haloalkenyl”, “haloalkenylalkyl”, “haloalkynyl”, “haloalkenyloxy”, “haloalkoxycarbonyl”, “haloalkylcarbonyloxy” and the like, are defined analogously to the term “haloalkyl”. Examples of “haloalkoxy” include CF_3O -, $\text{CCl}_3\text{CH}_2\text{O}$ -, $\text{HCF}_2\text{CH}_2\text{CH}_2\text{O}$ - and $\text{CF}_3\text{CH}_2\text{O}$ -.

5 Examples of “haloalkoxyalkyl” include CCl_3OCH_2 -, $\text{CF}_3\text{OCH}_2\text{CH}_2$ - and $\text{CCl}_3\text{CH}_2\text{CH}_2\text{CH}_2\text{O}$ -. Examples of “haloalkylthio” include CCl_3S -, CF_3S -, $\text{CCl}_3\text{CH}_2\text{S}$ - and $\text{ClCH}_2\text{CH}_2\text{CH}_2\text{S}$ -. Examples of “haloalkylsulfinyl” include $\text{CF}_3\text{S}(\text{O})$ -, $\text{CCl}_3\text{S}(\text{O})$ -, $\text{CF}_3\text{CH}_2\text{S}(\text{O})$ - and $\text{CF}_3\text{CF}_2\text{S}(\text{O})$ -. Examples of “haloalkylsulfonyl” include $\text{CF}_3\text{S}(\text{O})_2$ -, $\text{CCl}_3\text{S}(\text{O})_2$ -, $\text{CF}_3\text{CH}_2\text{S}(\text{O})_2$ - and $\text{CF}_3\text{CF}_2\text{S}(\text{O})_2$ -. Examples of “haloalkylsulfonyloxy” include $\text{CF}_3\text{S}(\text{O})_2\text{O}$ -, $\text{CCl}_3\text{S}(\text{O})_2\text{O}$ -, $\text{CF}_3\text{CH}_2\text{S}(\text{O})_2\text{O}$ - and $\text{CF}_3\text{CF}_2\text{S}(\text{O})_2\text{O}$ -. Examples of “haloalkenyl” and “haloalkenylalkyl” include $(\text{Cl})_2\text{C}=\text{CHCH}_2$ - and $\text{CF}_3\text{CH}_2\text{CH}=\text{CHCH}_2$ -. Examples of “haloalkynyl” include $\text{HC}\equiv\text{CCHCl}$ -, $\text{CF}_3\text{C}\equiv\text{C}$ -, $\text{CCl}_3\text{C}\equiv\text{C}$ - and $\text{FCH}_2\text{C}\equiv\text{CCH}_2$ -. Examples of “haloalkoxyalkoxy” include $\text{CF}_3\text{OCH}_2\text{O}$ -, $\text{ClCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{O}$ -, $\text{Cl}_3\text{CCH}_2\text{OCH}_2\text{O}$ - as well as branched alkyl derivatives. Examples of “haloalkenyloxy” include $\text{CF}_3\text{CH}=\text{CHO}$ -, $\text{ClCH}_2\text{CH}=\text{CHCH}_2\text{O}$ -, $\text{CH}_3\text{CCl}=\text{ClCH}_2\text{O}$ - as well as branched derivatives. Examples of “haloalkoxycarbonyl” include $\text{CF}_3\text{CH}_2\text{OC}(\text{=O})$ -, $\text{ClCH}_2\text{CH}_2\text{OC}(\text{=O})$ - and $\text{CH}_3\text{CCl}_2\text{CH}_2\text{OC}(\text{=O})$ -. Examples of “haloalkylcarbonyloxy” include $\text{CF}_3\text{CH}_2\text{C}(\text{=O})\text{O}$ -, $\text{ClCH}_2\text{CH}_2\text{C}(\text{=O})\text{O}$ - and $\text{CH}_3\text{CCl}_2\text{CH}_2\text{C}(\text{=O})\text{O}$ -.

“Alkylcarbonyl” denotes a straight-chain or branched alkyl moieties bonded to a 20 $\text{C}(\text{=O})$ moiety. Examples of “alkylcarbonyl” include $\text{CH}_3\text{C}(\text{=O})$ -, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}(\text{=O})$ - and $(\text{CH}_3)_2\text{CHC}(\text{=O})$ -. Examples of “alkylcarbonylalkyl” include $\text{CH}_3\text{C}(\text{=O})\text{CH}_2$ -, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}(\text{=O})\text{CH}_2$ - and $(\text{CH}_3)_2\text{CHC}(\text{=O})\text{CH}_2$ -. Examples of “alkoxycarbonyl” include $\text{CH}_3\text{OC}(\text{=O})$ -, $\text{CH}_3\text{CH}_2\text{OC}(\text{=O})$ -, $\text{CH}_3\text{CH}_2\text{CH}_2\text{OC}(\text{=O})$ -, $(\text{CH}_3)_2\text{CHOC}(\text{=O})$ - and the different butoxy- or pentoxy carbonyl isomers. “Alkylcarbonyloxy” denotes an 25 alkylcarbonyl moiety linked through an oxygen atom attached to the carbonyl. Examples of “alkylcarbonyloxy” include $\text{CH}_3\text{C}(\text{=O})\text{O}$ -, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}(\text{=O})\text{O}$ - and $(\text{CH}_3)_2\text{CHC}(\text{=O})\text{O}$ -. “Alkylcarbonylamino” denotes an alkylcarbonyl moiety linked through an amino moiety 30 atom attached to the carbonyl. Examples of “alkylcarbonylamino” include $\text{CH}_3\text{C}(\text{=O})\text{NH}$ -, $\text{CH}_3\text{CH}_2\text{CH}_2\text{C}(\text{=O})\text{NH}$ - and $(\text{CH}_3)_2\text{CHC}(\text{=O})\text{NH}$ -. “Cycloalkylaminocarbonyl” denotes 35 cycloalkyl substitution on an aminocarbonyl moiety. Examples of “cycloalkylaminocarbonyl” include *c*-PrNHC(=O)-, *c*-BuNHC(=O)- and *c*-HexNHC(=O)-. “Cycloalkylcarbonyl” denotes cycloalkyl substitution on a carbonyl moiety. Examples of 40 “cycloalkylcarbonyl” include *c*-PrC(=O)-, *c*-BuCH₂NHC(=O)- and *c*-HexCH₂NHC(=O)-. “Cycloalkylcarbonylalkyl” denotes cycloalkyl substitution on a carbonylalkyl moiety. Examples of “cycloalkylcarbonylalkyl” include *c*-PrC(=O)CH₂-, *c*-Bu(=O)CH₂CH₂- and *c*-HexC(=O)CH₂-.

The total number of carbon atoms in a substituent group is indicated by the “ $\text{C}_i\text{--C}_j$ ” prefix where i and j are numbers from 1 to 12. For example, $\text{C}_1\text{--C}_4$ alkylsulfonyl designates

methylsulfonyl through butylsulfonyl; C_2 alkoxyalkyl designates CH_3OCH_2- ; C_3 alkoxyalkyl designates, for example, $CH_3CH(OCH_3)-$, $CH_3OCH_2CH_2-$ or $CH_3CH_2OCH_2-$; and C_4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including 5 $CH_3CH_2CH_2OCH_2-$ and $CH_3CH_2OCH_2CH_2-$.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., $[(R^{10})_n]$, n is 1, 2, 3, 4 or 5). Further, when the subscript indicates a range, e.g. $(R)_{i-j}$, then the number of 10 substituents may be selected from the integers between i and j inclusive. When a group contains a substituent which can be hydrogen, for example $(R^1$ or R^6), then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for 15 example $[(R^{10})_n]$ wherein n may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be “not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency.

The expression “fully saturated” in relation to a ring of atoms means that the bonds between the atoms of the ring are all single. The expression “fully unsaturated” in relation to 20 a ring means that the bonds between the atoms in the ring are single or double bonds according to valence bond theory and furthermore the bonds between the atoms in the ring include as many double bonds as possible without double bonds being cumulative (i.e. no $C=C=C$, $N=C=C$, etc.). The term “partially unsaturated” in relation to a ring denotes a ring comprising at least one ring member bonded to an adjacent ring member through a double 25 bond and which conceptually potentially accommodates a number of non-cumulated double bonds through adjacent ring members (i.e. in its fully unsaturated counterpart form) greater than the number of double bonds present (i.e. in its partially unsaturated form). When a fully unsaturated ring satisfies Hückel’s rule then it can also be described as aromatic.

Unless otherwise indicated, a “ring” or “ring system” as a component of Formula 1 30 (e.g., substituent Q^1) is carbocyclic or heterocyclic. The term “ring system” denotes two or more fused rings. The terms “bicyclic ring system” denote a ring system consisting of two fused rings, in which either ring can be saturated, partially unsaturated, or fully unsaturated unless otherwise indicated. The term “ring member” refers to an atom or other moiety (e.g., $C(=O)$, $C(=S)$, $S(O)$ or $S(O)_2$) forming the backbone of a ring or ring system.

35 The terms “carbocyclic ring” or “carbocyclic ring system” denote a ring or ring system wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Hückel’s rule, then said



ring is also called an “aromatic ring”. “Saturated carbocyclic” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.

The terms “heterocyclic ring”, “heterocycle” or “heterocyclic ring system” denote a 5 ring or ring system in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heterocyclic ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a 10 fully unsaturated heterocyclic ring satisfies Hückel’s rule, then said ring is also called a “heteroaromatic ring”. The term “heteroaromatic bicyclic ring system” denotes a heterocyclic ring system in which at least one of the ring system is aromatic. Unless otherwise indicated, heterocyclic rings and ring systems can be attached through any 15 available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

“Aromatic” indicates that each of the ring atoms is essentially in the same plane and 15 has a *p*-orbital perpendicular to the ring plane, and that $(4n + 2)\pi$ electrons, where *n* is a positive integer, are associated with the ring to comply with Hückel’s rule. The term “aromatic ring system” denotes a carbocyclic or heterocyclic ring system in which at least one ring of the ring system is aromatic.

The term “optionally substituted” in connection with the heterocyclic rings refers to 20 groups which are unsubstituted or have at least one non-hydrogen substituent that does not extinguish the biological activity possessed by the unsubstituted analog. As used herein, the following definitions shall apply unless otherwise indicated. The term “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted.” Unless otherwise indicated, an optionally substituted group may 25 have a substituent at each substitutable position of the group, and each substitution is independent of the other.

As described in the Summary of the Invention, J can be either $-\text{CR}^2\text{R}^3-$; or $-\text{CR}^2\text{R}^3-\text{CR}^2\text{aR}^3\text{a}-$ wherein the $-\text{CR}^2\text{R}^3-$ moiety is directly connected to N. For example, when J is $-\text{CR}^2\text{R}^3-$, the compound of Formula 1 is represented by Formula 1A. When J is $-\text{CR}^2\text{R}^3-\text{CR}^2\text{aR}^3\text{a}-$, the compound of Formula 1 is represented by Formula 1B



where each of the remaining variables are defined in the Summary of the Invention.


As described in the Summary of the Invention, A can be a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3 atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, wherein up to 2 carbon members are independently selected from C(=O) and C(=S) and the sulfur atom member is selected from S(=O)_u(=NR⁸)_v; the said chain optionally substituted with up to 5 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms. Examples of A include -ON=CH-, -ON=C(CH₃)-, -NHN=CH-, -NHN=C(CH₃)-, -N=CH-, -N=C(CH₃)-, -CH=NO-, -C(CH₃)=NO-, -CH=NNH-, -C(CH₃)=NNH-, -CH=N-, -C(CH₃)=N-, -CH₂CH₂CH₂-, -CH₂CH₂-, -CH₂-, -CF₂-, -C(=O)-, -CH=CH-, -CH=CHCH₂-, -CH₂CH=CH-, -C≡C-, -C≡CCH₂-, -CH₂C≡C-, -CH₂CH₂O-, -CH₂O-, -O-, -OCH₂CH₂-, -OCH₂-, -CH₂CH₂S-, -CH₂S-, -S-, -SO-, -SO₂-, -SCH₂CH₂-, -SCH₂-, -CH₂CH₂NH-, -CH₂NH-, -NH-, -NHCH₂- and -NHCH₂CH₂- wherein the bond projecting to the left is connected to the Q¹ moiety, and the bond projecting to the right is connected to the remainder of Formula 1.


As noted above, Q¹ and Q² can be (among others) phenyl optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention. An example of phenyl optionally substituted with one to five substituents is the ring illustrated as U-1 in Exhibit 1, wherein, for example, R^v is R⁷ as defined in the Summary of the Invention for Q¹ and r is an integer (from 0 to 5); or R^v is R¹⁰ as defined in the Summary of the Invention for Q², and r is an integer (from 0 to 5); or R^v is R⁹ as defined in the Summary of the Invention for Q¹ and r is an integer (from 0 to 5) when R^v is bonded to nitrogen atom; or R^v is R¹¹ as defined in the Summary of the Invention for Q² and r is an integer (from 0 to 5) when R^v is bonded to nitrogen atom. In the Summary of the Invention R¹ can be arylcarbonyl, arylalkenylalkyl, arylcarbonylalkyl or -CPh=N-O(C₁-C₄ alkyl), each optionally substituted on ring members with up to 5 substituents independently selected from R¹³. In this context, the term the “aryl” can be substituted by R¹³ and is connected to the remainder of Formula 1 through a carbonyl group, an alkenylalkyl group or a carbonylalkyl group as defined above (e.g., aryl(C=O)-, aryl(C₂-C₈ alkenylalkyl)- or aryl(C=O)(C₁-C₄ alkyl)-). The phenyl group in the -CPh=N-O(C₁-C₄ alkyl) moiety can be further substituted by R¹³.

As noted above, Q¹ and Q² can be (among others) a 5- or 6-membered heteroaromatic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention. Examples of a 5- or 6-membered heteroaromatic ring optionally substituted with from one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein R^v is any substituent as defined in the Summary of the Invention for Q¹ and Q², and r is an integer from 0 to 4, limited by the number of available positions on each U group. As U-29, U-30, U-36, U-37, U-38, U-39, U-

40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1, and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by $(R^V)_r$.


Exhibit 1






As noted above, Q¹ and Q² can be (among others) an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention (i.e. R⁷ and R¹⁰). Examples of an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted with from one or more substituents include the rings U-62 through U-100 illustrated in Exhibit 2 wherein R^V is any substituent as defined in the Summary of the Invention for Q¹ or Q², and r is typically an integer from 0 to 5.

Exhibit 2





Although R^V groups are shown in the structures U-1 through U-100, it is noted that they do not need to be present since they are optional substituents. Note that when R^V is H when attached to an atom, this is the same as if said atom is unsubstituted. The nitrogen atoms that require substitution to fill their valence are substituted with H or R^V . Note that 5 when the attachment point between $(R^V)_r$ and the U group is illustrated as floating, $(R^V)_r$ can be attached to any available carbon atom or nitrogen atom of the U group. Note that when the attachment point on the U group is illustrated as floating, the U group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U group by replacement of a hydrogen atom. Note that some U groups can only be substituted with less 10 than 4 R^V groups (e.g., U-2 through U-5, U-7 through U-48, and U-52 through U-61).


A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings and ring systems; for extensive reviews see the eight volume set of *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of *Comprehensive*

Heterocyclic Chemistry II, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.


Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.

5 Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis-trans isomers (also known as geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active
10 and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. Particularly when R⁴ and R⁵ are each H, the C(O)N(Q²)(R⁶) and Q¹
15 substituents are typically mostly in the thermodynamically preferred trans configuration on the cyclic amide ring.

For example, the C(O)N(Q²)(R⁶) moiety (i.e. when each of Y¹ and Y² are O; and J is
20 –CR²R³–; and R² is H; and R³ is H) bonded to the carbon at the 3-position of the cyclic amide ring and –A–Q¹ (bonded to the carbon at the 4-position of the cyclic amide ring) are generally found in the *trans* configuration. The carbon atoms at both the 3- and 4-positions of each possess a chiral center. The most prevalent pair of enantiomers are depicted as
25 Formula 1' and Formula 1''. While this invention pertains to all stereoisomers, the preferred enantiomer for biological operability is identified as Formula 1'. The skilled artisan will understand the designation of R or S at a particular chiral center is a function of the specific substitution pattern at that center. For the compounds of Formulae 1' and 1'' may therefore be reversed depending on the value of the A variable. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, *Stereochemistry of
Organic Compounds*, John Wiley & Sons, 1994.



1'



1''

30 Molecular depictions drawn herein follow standard conventions for depicting stereochemistry. To indicate stereoconfiguration, bonds rising from the plane of the drawing

and towards the viewer are denoted by solid wedges wherein the broad end of the wedge is attached to the atom rising from the plane of the drawing towards the viewer. Bonds going below the plane of the drawing and away from the viewer are denoted by dashed wedges wherein the narrow end of the wedge is attached to the atom further away from the viewer.

5 Constant width lines indicate bonds with a direction opposite or neutral relative to bonds shown with solid or dashed wedges; constant width lines also depict bonds in molecules or parts of molecules in which no particular stereoconfiguration is intended to be specified.

This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1' and 1''. In addition, this invention includes compounds that are 10 enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1''.

When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess 15 ("ee"), which is defined as $(2x-1) \cdot 100\%$, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers).

Preferably the compositions of this invention have at least a 50% enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more 20 active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R⁷ and R¹⁰ may themselves contain 25 chiral centers. This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.

Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(O)N(Q²)(R⁶) when Y¹ is O) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.

30 Compounds of Formula 1 typically exist in more than one form, and Formula 1 thus include all crystalline and non-crystalline forms of the compounds they represent. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which 35 represent a mixture of polymorphs (i.e. different crystalline types). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical

composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, 5 dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound of Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound of Formula 1. Preparation and isolation of a particular polymorph of a compound of Formula 1 can be achieved by 10 methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., *Polymorphism in the Pharmaceutical Industry*, Wiley-VCH, Weinheim, 2006.

One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form *N*-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; 15 one skilled in the art will recognize those nitrogen-containing heterocycles which can form *N*-oxides. One skilled in the art will also recognize that tertiary amines can form *N*-oxides. Synthetic methods for the preparation of *N*-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and *m*-chloroperbenzoic acid (MCPBA), 20 hydrogen peroxide, alkyl hydroperoxides such as *t*-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of *N*-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in *Comprehensive Organic Synthesis*, vol. 7, pp 748–750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in *Comprehensive Heterocyclic Chemistry*, vol. 25 3, pp 18–20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in *Advances in Heterocyclic Chemistry*, vol. 43, pp 149–161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in *Advances in Heterocyclic Chemistry*, vol. 9, pp 285–291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in *Advances in Heterocyclic Chemistry*, vol. 22, 30 pp 390–392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of a compound of Formula 1 are useful for control of undesired 35 vegetation (i.e. are agriculturally suitable). The salts of a compound of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1

contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1,

5 *N*-oxides and agriculturally suitable salts thereof.

Embodiments of the present invention as described in the Summary of the Invention include (where Formula 1 as used in the following Embodiments includes *N*-oxides and salts thereof):

Embodiment 1. A compound of Formula 1 wherein A is

10 $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{N}-$, $-\text{OCH}_2-$, $-\text{NCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$,
 $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$ or $-\text{SO}_2-$ wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1.

15 Embodiment 2. A compound of Embodiment 1 wherein A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$,
 $-\text{CH}_2\text{N}-$, $-\text{OCH}_2-$, $-\text{NCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{N}-$ or $-\text{O}-$.

Embodiment 3. A compound of Embodiment 2 wherein A is $-\text{CH}_2-$.

20 Embodiment 4. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 3 wherein Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

25 Embodiment 5. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 3 wherein Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷.

Embodiment 6. A compound of Embodiment 5 wherein Q¹ is a phenyl ring substituted with up to 2 substituents independently selected from R⁷.

30 Embodiment 7. A compound of Embodiment 6 wherein Q¹ is a phenyl ring substituted with 1 substituent independently selected from R⁷.

35 Embodiment 8. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 7 wherein when Q² is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members.

Embodiment 9. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 7 wherein Q² is a phenyl ring substituted with up to 4 substituents independently selected from R¹⁰.

5 Embodiment 10. A compound of Embodiment 9 wherein Q² is a phenyl ring substituted with up to 3 substituents independently selected from R¹⁰.

Embodiment 11. A compound of Embodiment 10 wherein Q² is a phenyl ring substituted with up to 2 substituents independently selected from R¹⁰.

10 Embodiment 12. A compound of Embodiment 9 wherein Q² is a phenyl ring having at least one substituent selected from R¹⁰ at an ortho position (and optionally other substituents).

Embodiment 13. A compound of Embodiment 12 wherein Q² is a phenyl ring having 2 substituents selected from R¹⁰ and one of the said substituents is at an ortho position and the other said substituent is at meta or para position.

15 Embodiment 14. A compound of Embodiment 10 wherein when Q² is a phenyl ring substituted with three substituents selected from R¹⁰ and the three substituents are at an ortho (e.g., 2-), meta (e.g., 3-) and para (e.g., 4-) positions (of the phenyl ring).

Embodiment 15. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 14 wherein Y¹ is O.

20 Embodiment 16. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 15 wherein Y² is O.

Embodiment 17. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 16 wherein Y¹ and Y² are both O.

25 Embodiment 18. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 17 wherein J is -CR²R³-.

Embodiment 19. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 17 wherein J is -CR²R³-CR^{2a}R^{3a}-.

30 Embodiment 20. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 19 wherein R¹ is H, hydroxy, amino, cyano, formyl, C₃-C₈ alkylcarbonylalkyl, -C(C₁-C₄ alkyl)=N-O(C₁-C₄ alkyl), -C(O)NH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₂-C₈ alkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl or C₂-C₈ haloalkoxyalkyl.

35 Embodiment 21. A compound of Embodiment 20 wherein R¹ is H, hydroxy, amino, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl or C₄-C₈ cycloalkylalkyl.

Embodiment 22. A compound of Embodiment 21 wherein R¹ is H, C₁-C₆ alkyl or C₁-C₆ haloalkyl.

Embodiment 23. A compound of Embodiment 22 wherein R¹ is H, Me, Et or CHF₂.

Embodiment 24. A compound of Embodiment 23 wherein R¹ is H, Me or Et.

Embodiment 25. A compound of Embodiment 24 wherein R¹ is H.

Embodiment 26. A compound of Embodiment 24 wherein R¹ is Me.

5 Embodiment 27. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 26 wherein R² is H or CH₃.

Embodiment 28. A compound of Embodiment 27 wherein R² is H.

Embodiment 29. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 28 wherein R³ is H or CH₃.

10 Embodiment 30. A compound of Embodiment 29 wherein R³ is H.

Embodiment 31. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 30 wherein R^{2a} is H or CH₃.

Embodiment 32. A compound of Embodiment 31 wherein R^{2a} is H.

Embodiment 33. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 32 wherein R^{3a} is H or CH₃.

15 Embodiment 34. A compound of Embodiment 33 wherein R^{3a} is H.

Embodiment 35. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 34 wherein R⁴ is H or CH₃.

Embodiment 36. A compound of Embodiment 35 wherein R⁴ is H.

20 Embodiment 37. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 36 wherein R⁵ is H or CH₃.

Embodiment 38. A compound of Embodiment 37 wherein R⁵ is H.

Embodiment 39. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 38 wherein R⁶ is H, hydroxy, amino, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₃–C₈ 25 alkoxyalkoxyalkyl or C₂–C₈ haloalkoxyalkyl.

Embodiment 40. A compound of Embodiment 39 wherein R⁶ is H or CH₃.

Embodiment 41. A compound of Embodiment 40 wherein R⁶ is H.

Embodiment 42. A compound of Formula 1 or any one of Embodiment 1 through 30 Embodiment 41 wherein each R⁷ is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ 35 haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcycloalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈

haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy.

5 Embodiment 43. A compound of Embodiment 42 wherein each R⁷ is independently halogen, cyano, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl.

Embodyment 44. A compound of Embodiment 43 each wherein R⁷ is independently halogen or C₁–C₂ haloalkyl.

10 Embodiment 45. A compound of Embodiment 44 wherein each R⁷ is independently halogen or CF₃.

Embodyment 46. A compound of Embodiment 45 wherein each R⁷ is independently F, Cl or CF₃.

Embodyment 47. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 46 wherein each R¹⁰ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl or C₃–C₈ cycloalkyl.

20 Embodiment 48. A compound of Embodiment 47 wherein each R¹⁰ is independently halogen, cyano, nitro, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl.

Embodyment 49. A compound of Embodiment 48 wherein each R¹⁰ is independently halogen or C₁–C₂ haloalkyl.

25 Embodiment 50. A compound of Embodiment 49 wherein each R¹⁰ is independently halogen or CF₃.

Embodyment 51. A compound of Embodiment 50 wherein each R¹⁰ is independently F or CF₃.

30 Embodiment 52. A compound of Embodiment 51 wherein each R¹⁰ is independently F.

Embodyment 53. A compound of any one Embodiments 1, 2 or 4 through 52 wherein A is -CH₂–, -(CH₂)₂C(=O)NH–, -CH₂CH₂–, -C(=O)NH–, -CH₂NH–, -OCH₂–, -NHCH₂–, -CH=CH–, -C≡C–, -N–, -O–, -S–, -SO– or -SO₂– wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1.

35 Embodiment 54. A compound of Embodiment 54 wherein A is -CH₂–, -CH₂CH₂–, -C(=O)NH–, -CH=CH– or -C≡C– wherein the bond projecting to the left is

connected to the Q¹ moiety, and the bond projecting to the right is connected to the remainder of Formula 1.

Embodiment 55. A compound of Embodiment 54 wherein A is —CH₂—, —CH₂CH₂—, —CH=CH— or —C≡C—.

5 Embodiment 56. A compound of Embodiment 55 wherein A is —CH₂—.

Embodiment 57. A compound of Embodiment 55 wherein A is —CH₂CH₂—.

Embodiment 58. A compound of Embodiment 56 wherein A is —CH=CH—.

Embodiment 59. A compound of Embodiment 56 wherein A is —C≡C—.


10 Embodiment 60. A compound of Embodiment 1 wherein Q¹ is an 8- to 10-membered heteroaromatic bicyclic ring system, each ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O and up to 2 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), each ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

15 Embodiment 61. A compound of Embodiment 60 wherein Q¹ is an 8- to 9-membered heteroaromatic bicyclic ring system, each ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O atoms, each ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members.

20 Embodiment 62. A compound of Embodiment 61 wherein Q¹ is an 9-membered heteroaromatic bicyclic ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O atoms, each ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members.

25 Embodiment 63. A compound of Embodiment 62 wherein Q¹ is an 9-membered heteroaromatic bicyclic ring system containing ring members selected from carbon atoms and 2 O atoms, system optionally substituted with up to 3 substituents independently selected from R⁷ on carbon atom ring members (i.e. U-81 in Exhibit 2).

30 Embodiment 64. A compound of Embodiment 63 wherein Q¹ is U-81A;



Embodiment 65. A compound of Formula 1 or any one of Embodiments 1 through 3, 5 or 8 through 64 wherein Q¹ is a phenyl ring optionally substituted with 1 to 4 substituents independently selected from R⁷; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

Embodiment 66. A compound of Formula 1 or any one of Embodiments 1 through 7 or 15 through 65 wherein Q² is a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹¹ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members.

Embodiment 67. A compound of Embodiment 66 wherein Q² is a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 4 N atoms, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹¹ on carbon atom ring members.

Embodiment 68. A compound of Embodiment 67 wherein Q² is a phenyl ring optionally substituted with up to 4 substituents independently selected from R¹⁰; or a pyridyl ring, optionally substituted with up to 4 substituents independently selected from R¹¹ on carbon atom ring members.

Embodiment 69. A compound of Embodiment 68 wherein Q² is a 3-pyridyl ring optionally substituted with up to 3 substituents independently selected from R¹⁰ on carbon atom ring members.

Embodiment 70. A compound of Embodiment 69 wherein Q² is a 3-pyridyl ring optionally substituted with up to 3 substituents independently selected from C₁–C₈ alkyl or C₁–C₈ haloalkyl.

Embodiment 71. A compound of Formula 1 wherein A is –CH₂–, –CH₂O–, –CH₂NH–, –OCH₂–, –NHCH₂–, –CH=CH–, –C≡C–, –NH–, –O–, –S–, –SO– or –SO₂– wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1.

Embodiment 72. A compound of Forumula **2** wherein A is wherein A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NH}-$, $-\text{OCH}_2-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$ or $-\text{O}-$.

Embodiment 73. A compound of Formula **1** wherein A is selected from $-\text{ON}=\text{CH}-$, $-\text{ON}=\text{C}(\text{CH}_3)-$, $-\text{NHN}=\text{CH}-$, $-\text{NHN}=\text{C}(\text{CH}_3)-$, $-\text{N}=\text{CH}-$, $-\text{N}=\text{C}(\text{CH}_3)-$, $-\text{CH}=\text{NO}-$, $-\text{C}(\text{CH}_3)=\text{NO}-$, $-\text{CH}=\text{NNH}-$, $-\text{C}(\text{CH}_3)=\text{NNH}-$, $-\text{CH}=\text{N}-$, $-\text{C}(\text{CH}_3)=\text{N}-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2-$, $-\text{CF}_2-$, $-\text{C}(\text{=O})-$, $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CHCH}_2-$, $-\text{CH}_2\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCH}_2-$, $-\text{CH}_2\text{C}\equiv\text{C}-$, $-\text{CH}_2\text{CH}_2\text{O}-$, $-\text{CH}_2\text{O}-$, $-\text{O}-$, $-\text{OCH}_2\text{CH}_2-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{CH}_2\text{S}-$, $-\text{CH}_2\text{S}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{SCH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{NH}-$, $-\text{NH}-$, $-\text{NHCH}_2-$ and $-\text{NHCH}_2\text{CH}_2-$, wherein the bond projecting to the left is connected to the Q¹ moiety, and the bond projecting to the right is connected to the remainder of Formula **1**.

Embodiment 74. A compound of Embodiment 73 wherein A is selected from $-\text{ON}=\text{CH}-$, $-\text{ON}=\text{C}(\text{CH}_3)-$, $-\text{NHN}=\text{CH}-$, $-\text{NHN}=\text{C}(\text{CH}_3)-$, $-\text{N}=\text{CH}-$, $-\text{N}=\text{C}(\text{CH}_3)-$, $-\text{CH}=\text{NO}-$, $-\text{C}(\text{CH}_3)=\text{NO}-$, $-\text{CH}=\text{NNH}-$, $-\text{C}(\text{CH}_3)=\text{NNH}-$, $-\text{CH}=\text{N}-$ and $-\text{C}(\text{CH}_3)=\text{N}-$.

Embodiment 75. A compound of Embodiment 74 wherein A is selected from $-\text{ON}=\text{CH}-$, $-\text{ON}=\text{C}(\text{CH}_3)-$, $-\text{NHN}=\text{CH}-$, $-\text{NHN}=\text{C}(\text{CH}_3)-$, $-\text{N}=\text{CH}-$, and $-\text{N}=\text{C}(\text{CH}_3)-$.

Embodiment 76. A compound of Embodiment 74 wherein A is selected from $-\text{CH}=\text{NO}-$, $-\text{C}(\text{CH}_3)=\text{NO}-$, $-\text{CH}=\text{NNH}-$, $-\text{C}(\text{CH}_3)=\text{NNH}-$, $-\text{CH}=\text{N}-$ and $-\text{C}(\text{CH}_3)=\text{N}-$.

Embodiment 77. A compound of Formula **1** wherein R¹⁵ is other than C₄–C₈ cycloalkylalkyl.

Embodiments of this invention, including Embodiments 1 through 77 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula **1** but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula **1**. In addition, embodiments of this invention, including Embodiments 1–77 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.

Combinations of Embodiments 1–77 are illustrated by:

Embodiment A. A compound of Formula **1** wherein

A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NH}-$, $-\text{OCH}_2-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$ or $-\text{O}-$ wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula **1**;

Q¹ is a phenyl ring substituted with up to 2 substituents independently selected from R⁷;

Q² is a phenyl ring substituted with up to 3 substituents independently selected from R¹⁰;

5 Y¹ and Y² are both O; and
J is -CR²R³-.

Embodiment B. A compound of Formula 1 wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -OCH₂-, -NHCH₂-, -CH=CH-, -C≡C-, -NH- or -O- wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1;

10 Q¹ is a phenyl ring substituted with up to 2 substituents independently selected from R⁷;

Q² is a phenyl ring substituted with up to 3 substituents independently selected from R¹⁰;

15 Y¹ and Y² are both O; and
J is -CR²R³-CR^{2a}R^{3a}-.

Embodiment C. A compound of Embodiment A wherein

20 A is -CH₂-;

R¹ is H, Me or Et;

R² is H;

R³ is H;

R⁴ is H;

R⁵ is H;

25 R⁶ is H;

R⁷ is independently is independently halogen, cyano, nitro, C₁-C₈ alkyl, C₂-C₈ cyanoalkyl, C₁-C₈ cyanoalkoxy, C₁-C₈ haloalkyl, C₂-C₈ alkenyl, C₂-C₈ haloalkenyl, C₂-C₈ alkynyl, C₂-C₈ haloalkynyl, C₁-C₈ nitroalkyl, C₂-C₈ nitroalkenyl, C₂-C₈ alkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀ alkylcyclolalkyl, C₁-C₈ alkoxy, C₁-C₈ haloalkoxy, C₂-C₈ alkenyloxy, C₂-C₈ haloalkenyloxy, C₃-C₈ alkynyloxy, C₃-C₈ haloalkynyloxy, C₃-C₈ cycloalkoxy, C₁-C₈ alkylthio, C₁-C₈ haloalkylthio, C₁-C₈ alkylsulfinyl, C₁-C₈ haloalkylsulfinyl, C₁-C₈ alkylsulfonyl, C₁-C₈ haloalkylsulfonyl, hydroxy, formyl, C₂-C₈ alkylcarbonyl, C₂-C₈ alkylcarbonyloxy, C₁-C₈ alkylsulfonyloxy, C₁-C₈ haloalkylsulfonyloxy, amino, C₁-C₄ alkylamino, C₂-C₄ dialkylamino, formylamino, C₂-C₄

alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

R¹⁰ is independently halogen, cyano, nitro, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl.

5 Embodiment D. A compound of Embodiment B wherein

A is –CH₂–;

R¹ is H, Me or Et;

R² is H;

R³ is H;

10 R^{2a} is H;

R^{3a} is H;

R⁴ is H;

R⁵ is H;

R⁶ is H;

15 R⁷ is independently is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀

20 cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈

25 alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

30 R¹⁰ is independently halogen, cyano, nitro, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl.

Embodiment E. A compound of Embodiment C wherein

each R⁷ is independently halogen, cyano, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl; and

each R¹⁰ is independently halogen or C₁–C₂ haloalkyl.

35 Embodiment F. A compound of Embodiment E wherein

Q¹ is a phenyl ring substituted with 1 substituent independently selected from R⁷;

Q^2 is a phenyl ring having 2 substituents selected from R^{10} and one of the said substituents is at an ortho position and the other said substituent is at meta or para position.

Embodiment G. A compound of Embodiment E wherein

5 Q^2 is a phenyl ring substituted with three substituents selected from R^{10} and the three substituents are at an ortho, meta and para positions of the phenyl ring.

Embodiment H. A compound of Formula 1 wherein

A is selected from $-ON=CH-$, $-ON=C(CH_3)-$, $-NHN=CH-$, $-NHN=C(CH_3)-$,
10 $-N=CH-$, $-N=C(CH_3)-$, $-CH=NO-$, $-C(CH_3)=NO-$, $-CH=NNH-$,
 $-C(CH_3)=NNH-$, $-CH=N-$, $-C(CH_3)=N-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2-$,
 $-CH_2-$, $-CF_2-$, $-C(=O)-$, $-CH=CH-$, $-CH=CHCH_2-$, $-CH_2CH=CH-$, $-C\equiv C-$,
 $-C\equiv CCH_2-$, $-CH_2C\equiv C-$, $-CH_2CH_2O-$, $-CH_2O-$, $-O-$, $-OCH_2CH_2-$, $-OCH_2-$,
15 $-CH_2CH_2S-$, $-CH_2S-$, $-S-$, $-SO-$, $-SO_2-$, $-SCH_2CH_2-$, $-SCH_2-$,
 $-CH_2CH_2NH-$, $-CH_2NH-$, $-NH-$, $-NHCH_2-$ and $-NHCH_2CH_2-$, wherein the bond projecting to the left is connected to the Q^1 moiety, and the bond projecting to the right is connected to the remainder of Formula 1;

20 Q^1 is a phenyl ring optionally substituted with 1 to 4 substituents independently selected from R^7 ; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members;

25 Q^2 is a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{10} ; or a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{11} on carbon atom ring members and selected from R^{11} on nitrogen atom ring members;

30 Y^1 and Y^2 are both O;

35 R^1 is H, hydroxy, amino, cyano, formyl, C_3-C_8 alkylcarbonylalkyl, $-C(C_1-C_4$ alkyl)= $N-O(C_1-C_4$ alkyl), $-C(O)NH_2$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_3-C_6 alkynyl, C_2-C_6 cyanoalkyl, C_3-C_6 cycloalkyl, C_4-C_8 cycloalkylalkyl, C_2-C_8 alkoxyalkyl, C_3-C_8 alkoxyalkoxyalkyl or C_2-C_8 haloalkoxyalkyl;

40 R^6 is H, hydroxy, amino, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_3-C_6 alkynyl, C_2-C_8 alkoxyalkyl, C_3-C_8 alkoxyalkoxyalkyl or C_2-C_8 haloalkoxyalkyl;

each R⁷ is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and each R¹⁰ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl or C₃–C₈ cycloalkyl.

Specific embodiments include compounds of Formula 1 selected from the group

20 consisting of:

N-(2,3-difluorophenyl)-4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxamide (Compound 13); and 4-[(3-chlorophenyl)methyl]-N-(2,3-difluorophenyl)-2-oxo-3-pyrrolidinecarboxamide (Compound 1).

25 This invention also relates to a method for controlling undesired vegetation comprising applying to the locus of the vegetation herbicidally effective amounts of the compounds of the invention (e.g., as a composition described herein). Of note as embodiments relating to methods of use are those involving the compounds of embodiments described above. Compounds of the invention are particularly useful for selective control of weeds in crops 30 such as wheat, barley, maize, soybean, sunflower, cotton, oilseed rape and rice, and specialty crops such as sugarcane, citrus, fruit and nut crops.

Also noteworthy as embodiments are herbicidal compositions of the present invention comprising the compounds of embodiments described above.

This invention also includes a herbicidal mixture comprising (a) a compound selected 35 from Formula 1, N-oxides, and salts thereof, and (b) at least one additional active ingredient selected from (b1) photosystem II inhibitors, (b2) acetohydroxy acid synthase (AHAS) inhibitors, (b3) acetyl-CoA carboxylase (ACCase) inhibitors, (b4) auxin mimics, (b5) 5-enol-pyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, (b6) photosystem I

electron diverters, (b7) protoporphyrinogen oxidase (PPO) inhibitors, (b8) glutamine synthetase (GS) inhibitors, (b9) very long chain fatty acid (VLCFA) elongase inhibitors, (b10) auxin transport inhibitors, (b11) phytoene desaturase (PDS) inhibitors, (b12) 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors, (b13) homogentisate solenesyltransferase (HST) inhibitors, (b14) cellulose biosynthesis inhibitors, (b15) other herbicides including mitotic disruptors, organic arsenicals, asulam, bromobutide, cinmethylin, cumyluron, dazomet, difenzoquat, dymron, etobenzanid, flurenol, fosamine, fosamine-ammonium, hydantocidin, metam, methyldymron, oleic acid, oxaziclofene, pelargonic acid and pyributicarb, and (b16) herbicide safeners; and salts of compounds of (b1) through (b16).

“Photosystem II inhibitors” (b1) are chemical compounds that bind to the D-1 protein at the Q_B -binding niche and thus block electron transport from Q_A to Q_B in the chloroplast thylakoid membranes. The electrons blocked from passing through photosystem II are transferred through a series of reactions to form toxic compounds that disrupt cell membranes and cause chloroplast swelling, membrane leakage, and ultimately cellular destruction. The Q_B -binding niche has three different binding sites: binding site A binds the triazines such as atrazine, triazinones such as hexazinone, and uracils such as bromacil, binding site B binds the phenylureas such as diuron, and binding site C binds benzothiadiazoles such as bentazon, nitriles such as bromoxynil and phenyl-pyridazines such as pyridate. Examples of photosystem II inhibitors include ametryn, amicarbazone, atrazine, bentazon, bromacil, bromofenoxim, bromoxynil, chlorbromuron, chloridazon, chlorotoluron, chloroxuron, cumyluron, cyanazine, daimuron, desmedipham, desmetryn, dimefuron, dimethametryn, diuron, ethidimuron, fenuron, fluometuron, hexazinone, ioxynil, isoproturon, isouron, lenacil, linuron, metamitron, methabenzthiazuron, metobromuron, metoxuron, metribuzin, monolinuron, neburon, pentanochlor, phenmedipham, prometon, prometryn, propanil, propazine, pyridafol, pyridate, siduron, simazine, simetryn, tebuthiuron, terbacil, terbumeton, terbutylazine, terbutryn and trietazine. Of note is a compound of the invention mixed with atrazine, bromoxynil or metribuzin.

“AHAS inhibitors” (b2) are chemical compounds that inhibit acetohydroxy acid synthase (AHAS), also known as acetolactate synthase (ALS), and thus kill plants by inhibiting the production of the branched-chain aliphatic amino acids such as valine, leucine and isoleucine, which are required for protein synthesis and cell growth. Examples of AHAS inhibitors include amidosulfuron, azimsulfuron, bensulfuron-methyl, bispyribac-sodium, cloransulam-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, diclosulam, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, florasulam, flucarbazone-sodium, flumetsulam, flupyrifluor-methyl, flupyrifluor-sodium, foramsulfuron, halosulfuron-methyl, imazamethabenz-methyl, imazamox, imazapic, imazapir, imazaquin, imazethapir, imazosulfuron, iodosulfuron-methyl (including sodium

salt), iofensulfuron (2-*iodo*-*N*-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]benzenesulfonamide), mesosulfuron-methyl, metazosulfuron (3-chloro-4-(5,6-dihydro-5-methyl-1,4,2-dioxazin-3-yl)-*N*-[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-1-methyl-1*H*-pyrazole-5-sulfonamide), metosulam, 5 metsulfuron-methyl, nicosulfuron, oxasulfuron, penoxsulam, primisulfuron-methyl, propoxycarbazone-sodium, propyrisulfuron (2-chloro-*N*-[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-6-propylimidazo[1,2-*b*]pyridazine-3-sulfonamide), prosulfuron, pyrazosulfuron-ethyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrithiobac-sodium, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thiencarbazone, 10 thifensulfuron-methyl, triafamone (*N*-[2-[(4,6-dimethoxy-1,3,5-triazin-2-yl)carbonyl]-6-fluorophenyl]-1,1-difluoro-*N*-methylmethanesulfonamide), triasulfuron, tribenuron-methyl, trifloxsulfuron (including sodium salt), triflusulfuron-methyl and tritosulfuron. Of note is a compound of the invention mixed with nicosulfuron, fluprysulfuron or chlorimuron.

“ACCase inhibitors” (b3) are chemical compounds that inhibit the acetyl-CoA carboxylase enzyme, which is responsible for catalyzing an early step in lipid and fatty acid synthesis in plants. Lipids are essential components of cell membranes, and without them, new cells cannot be produced. The inhibition of acetyl CoA carboxylase and the subsequent lack of lipid production leads to losses in cell membrane integrity, especially in regions of active growth such as meristems. Eventually shoot and rhizome growth ceases, and shoot 15 meristems and rhizome buds begin to die back. Examples of ACCase inhibitors include aloxydim, butoxydim, clethodim, clodinafop, cycloxydim, cyhalofop, diclofop, fenoxaprop, fluazifop, haloxyfop, pinoxaden, profoxydim, propaquizafop, quizalofop, sethoxydim, tepraloxydim and tralkoxydim, including resolved forms such as fenoxaprop-P, 20 fluazifop-P, haloxyfop-P and quizalofop-P and ester forms such as clodinafop-propargyl, fluazifop-butyl, diclofop-methyl and fenoxaprop-P-ethyl. Of note is a compound of the 25 invention mixed with pinoxaden or quizalofop.

Auxin is a plant hormone that regulates growth in many plant tissues. “Auxin mimics” (b4) are chemical compounds mimicking the plant growth hormone auxin, thus causing uncontrolled and disorganized growth leading to plant death in susceptible species. 30 Examples of auxin mimics include aminocyclopyrachlor (6-amino-5-chloro-2-cyclopropyl-4-pyrimidinecarboxylic acid) and its methyl and ethyl esters and its sodium and potassium salts, aminopyralid, benazolin-ethyl, chloramben, clacyfos, clomeprop, clopyralid, dicamba, 2,4-D, 2,4-DB, dichlorprop, fluroxypyr, halauxifen (4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylic acid), halauxifen-methyl (methyl 4-amino-3-chloro-35 6-(4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylate), MCPA, MCPB, mecoprop, picloram, quinclorac, quinmerac, 2,3,6-TBA, triclopyr, and methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-5-fluoro-2-pyridinecarboxylate. Of note is a compound of the invention mixed with dicamba.

“EPSP synthase inhibitors” (b5) are chemical compounds that inhibit the enzyme, 5-enol-pyruvylshikimate-3-phosphate synthase, which is involved in the synthesis of aromatic amino acids such as tyrosine, tryptophan and phenylalanine. EPSP inhibitor herbicides are readily absorbed through plant foliage and translocated in the phloem to the growing points. Glyphosate is a relatively nonselective postemergence herbicide that belongs to this group. Glyphosate includes esters and salts such as ammonium, isopropylammonium, potassium, sodium (including sesquisodium) and trimesium (alternatively named sulfosate).

“Photosystem I electron diverters” (b6) are chemical compounds that accept electrons from Photosystem I, and after several cycles, generate hydroxyl radicals. These radicals are extremely reactive and readily destroy unsaturated lipids, including membrane fatty acids and chlorophyll. This destroys cell membrane integrity, so that cells and organelles “leak”, leading to rapid leaf wilting and desiccation, and eventually to plant death. Examples of this second type of photosynthesis inhibitor include diquat and paraquat.

“PPO inhibitors” (b7) are chemical compounds that inhibit the enzyme protoporphyrinogen oxidase, quickly resulting in formation of highly reactive compounds in plants that rupture cell membranes, causing cell fluids to leak out. Examples of PPO inhibitors include acifluorfen-sodium, azafenidin, benzfendizone, bifenox, butafenacil, carfentrazone, carfentrazone-ethyl, chlomethoxyfen, cinidon-ethyl, fluazolate, flufenpyr-ethyl, flumiclorac-pentyl, flumioxazin, fluoroglycofen-ethyl, fluthiacet-methyl, fomesafen, halosafen, lactofen, oxadiargyl, oxadiazon, oxyfluorfen, pentozacone, profluazol, pyraclonil, pyraflufen-ethyl, saflufenacil, sulfentrazone, thidiazimin, trifludimoxazin (dihydro-1,5-dimethyl-6-thioxo-3-[2,2,7-trifluoro-3,4-dihydro-3-oxo-4-(2-propyn-1-yl)-2H-1,4-benzoxazin-6-yl]-1,3,5-triazine-2,4(1H,3H)-dione) and tiafenacil (methyl *N*-[2-[2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]thio]-1-oxopropyl]- β -alaninate).

“GS inhibitors” (b8) are chemical compounds that inhibit the activity of the glutamine synthetase enzyme, which plants use to convert ammonia into glutamine. Consequently, ammonia accumulates and glutamine levels decrease. Plant damage probably occurs due to the combined effects of ammonia toxicity and deficiency of amino acids required for other metabolic processes. The GS inhibitors include glufosinate and its esters and salts such as glufosinate-ammonium and other phosphinothrinicin derivatives, glufosinate-P ((2S)-2-amino-4-(hydroxymethylphosphinyl)butanoic acid) and bilanaphos.

“VLCFA elongase inhibitors” (b9) are herbicides having a wide variety of chemical structures, which inhibit the elongase. Elongase is one of the enzymes located in or near chloroplasts which are involved in biosynthesis of VLCFAs. In plants, very-long-chain fatty acids are the main constituents of hydrophobic polymers that prevent desiccation at the leaf surface and provide stability to pollen grains. Such herbicides include acetochlor, alachlor,

anilofos, butachlor, cafenstrole, dimethachlor, dimethenamid, diphenamid, fenoxasulfone (3-[[2,5-dichloro-4-ethoxyphenyl)methyl]sulfonyl]-4,5-dihydro-5,5-dimethylisoxazole), fentrazamide, flufenacet, indanofan, mefenacet, metazachlor, metolachlor, naproanilide, napropamide, napropamide-M ((2R)-*N,N*-diethyl-2-(1-naphthalenyl)propanamide), 5 pethoxamid, piperophos, pretilachlor, propachlor, propisochlor, pyroxasulfone, and thenylchlor, including resolved forms such as S-metolachlor and chloroacetamides and oxyacetamides. Of note is a compound of the invention mixed with flufenacet.


“Auxin transport inhibitors” (b10) are chemical substances that inhibit auxin transport in plants, such as by binding with an auxin-carrier protein. Examples of auxin transport 10 inhibitors include diflufenzopyr, naptalam (also known as *N*-(1-naphthyl)phthalamic acid and 2-[(1-naphthalenylamino)carbonyl]benzoic acid).

“PDS inhibitors” (b11) are chemical compounds that inhibit carotenoid biosynthesis pathway at the phytoene desaturase step. Examples of PDS inhibitors include beflubutamid, diflufenican, fluridone, flurochloridone, flurtamone norflurzon and picolinafen.

15 “HPPD inhibitors” (b12) are chemical substances that inhibit the biosynthesis of synthesis of 4-hydroxyphenyl-pyruvate dioxygenase. Examples of HPPD inhibitors include benzobicyclon, benzofenap, bicycloprone (4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]bicyclo[3.2.1]oct-3-en-2-one), fenquinotrione (2-[[8-chloro-3,4-dihydro-4-(4-methoxyphenyl)-3-oxo-2-quinoxalinyl]carbonyl]-1,3-cyclohexanedione), isoxachlortole, isoxaflutole, mesotrione, pyrasulfotole, pyrazolynate, 20 pyrazoxyfen, sulcotrione, tefuryltrione, tembotrione, tolpyralate (1-[[1-ethyl-4-[3-(2-methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl]-1*H*-pyrazol-5-yl]oxy]ethyl methyl carbonate), topramezone, 5-chloro-3-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-1-(4-methoxyphenyl)-2(1*H*)-quinoxalinone, 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-dimethyl-3(2*H*)-pyridazinone, 4-(4-fluorophenyl)-6-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-methyl-1,2,4-triazine-3,5(2*H,4H*)-dione, 5-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-(3-methoxyphenyl)-3-(3-methoxypropyl)-4(3*H*)-pyrimidinone, 2-methyl-*N*-(4-methyl-1,2,5-oxadiazol-3-yl)-3-(methylsulfinyl)-4-(trifluoromethyl)benzamide and 25 2-methyl-3-(methylsulfonyl)-*N*-(1-methyl-1*H*-tetrazol-5-yl)-4-(trifluoromethyl)benzamide. Of note is a compound of the invention mixed with mesotrione or pyrasulfotole.

30 “HST inhibitors” (b13) disrupt a plant’s ability to convert homogentisate to 2-methyl-6-solanyl-1,4-benzoquinone, thereby disrupting carotenoid biosynthesis. Examples of HST inhibitors include haloxydine, cyclopyrimorate (6-chloro-3-(2-cyclopropyl-6-methylphenoxy)-4-pyridazinyl 4-morpholinecarboxylate), pyriclor, 3-(2-chloro-3,6-difluorophenyl)-4-hydroxy-1-methyl-1,5-naphthyridin-2(1*H*)-one, 7-(3,5-dichloro-4-pyridinyl)-5-(2,2-difluoroethyl)-8-hydroxypyrido[2,3-*b*]pyrazin-6(5*H*)-one and 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-dimethyl-3(2*H*)-pyridazinone.

HST inhibitors also include compounds of Formulae **A** and **B**.



wherein R^{d1} is H, Cl or CF_3 ; R^{d2} is H, Cl or Br; R^{d3} is H or Cl; R^{d4} is H, Cl or CF_3 ; R^{d5} is CH_3 , CH_2CH_3 or CH_2CHF_2 ; and R^{d6} is OH, or $-OC(=O)-i-Pr$; and R^{e1} is H, F, Cl, CH_3 or CH_2CH_3 ; R^{e2} is H or CF_3 ; R^{e3} is H, CH_3 or CH_2CH_3 ; R^{e4} is H, F or Br; R^{e5} is Cl, CH_3 , CF_3 , OCF_3 or CH_2CH_3 ; R^{e6} is H, CH_3 , CH_2CHF_2 or $C\equiv CH$; R^{e7} is OH, $-OC(=O)Et$, $-OC(=O)-i-Pr$ or $-OC(=O)-t-Bu$; and A^{e8} is N or CH.

5 CH_3 , CF_3 , OCF_3 or CH_2CH_3 ; Re^6 is H , CH_3 , CH_2CHF_2 or $\text{C}\equiv\text{CH}$; Re^7 is OH , $-\text{OC}(=\text{O})\text{Et}$, $-\text{OC}(=\text{O})-\text{i-Pr}$ or $-\text{OC}(=\text{O})-\text{t-Bu}$; and A^8 is N or CH .

“Cellulose biosynthesis inhibitors” (b14) inhibit the biosynthesis of cellulose in certain plants. They are most effective when applied preemergence or early postemergence on young or rapidly growing plants. Examples of cellulose biosynthesis inhibitors include chlorthiamid, dichlobenil, flupoxam, indaziflam (N^2 -[(1*R*,2*S*)-2,3-dihydro-2,6-dimethyl-1*H*-inden-1-yl]-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine), isoxaben and triaziflam.

“Other herbicides” (b15) include herbicides that act through a variety of different modes of action such as mitotic disruptors (e.g., flamprop-M-methyl and flamprop-M-isopropyl), organic arsenicals (e.g., DSMA, and MSMA), 7,8-dihydropteroate synthase inhibitors, chloroplast isoprenoid synthesis inhibitors and cell-wall biosynthesis inhibitors. Other herbicides include those herbicides having unknown modes of action or do not fall into a specific category listed in (b1) through (b14) or act through a combination of modes of action listed above. Examples of other herbicides include aclonifen, asulam, amitrole, bromobutide, cinmethylin, clomazone, cumyluron, daimuron, difenzoquat, etobenzanid, fluometuron, flurenol, fosamine, fosamine-ammonium, dazomet, dymron, ipfencarbazone (1-(2,4-dichlorophenyl)-N-(2,4-difluorophenyl)-1,5-dihydro-*N*-(1-methylethyl)-5-oxo-4*H*-1,2,4-triazole-4-carboxamide), metam, methyldymron, oleic acid, oxaziclofone, pelargonic acid, pyributicarb and 5-[[[(2,6-difluorophenyl)methoxy]methyl]-4,5-dihydro-5-methyl-3-(3-methyl-2-thienyl)isoxazole.


25 "Herbicide safeners" (b16) are substances added to a herbicide formulation to eliminate or reduce phytotoxic effects of the herbicide to certain crops. These compounds protect crops from injury by herbicides but typically do not prevent the herbicide from controlling undesired vegetation. Examples of herbicide safeners include but are not limited to benoxacor, cloquintocet-methyl, cumyluron, cyometrinil, cyprosulfamide, daimuron, 30 dichlormid, dicycloron, diethololate, dimepiperate, fenchlorazole-ethyl, fenclorim, flurazole,

fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, mephenate, methoxyphenone, naphthalic anhydride, oxabetrinil, *N*-(aminocarbonyl)-2-methylbenzenesulfonamide and *N*-(aminocarbonyl)-2-fluorobenzenesulfonamide, 1-bromo-4-[(chloromethyl)sulfonyl]benzene, 2-(dichloromethyl)-2-methyl-1,3-dioxolane (MG 191), 4-(dichloroacetyl)-1-oxa-4-azospiro[4.5]decane (MON 4660), 2,2-dichloro-1-(2,2,5-trimethyl-3-oxazolidinyl)-ethanone and 2-methoxy-*N*-[[4-[(methylamino)carbonyl]amino]phenyl]sulfonyl]-benzamide.

The compounds of Formula 1 can be prepared by general methods known in the art of synthetic organic chemistry. One or more of the following methods and variations as 10 described in Schemes 1–19 can be used to prepare the compounds of Formula 1. The definitions of R¹, R², R³, R⁴, R⁵, R⁶, Q¹, Q², J, A, Y¹, and Y² in the compounds of Formulae 1–19 below are as defined above in the Summary of the Invention unless otherwise noted. The compounds of Formulae 1a, 1b, 1aa, 1ab, 1ba, 1bb, 1c, 1d, 1e, 1f, 1g, 15 1g', 1h, 2', 4a, 4b, 5a, 5b, 5c, 5d, 5a', 5b', 7a, 7b, 8a, 8b, 10a and 10b are various subsets of a compound of Formulae 1, 2, 4, 5, 7, 8 and 10 respectively


As shown in Scheme 1 a compound of Formula 1a (i.e. Formula 1 wherein R¹, R⁴ and R⁵ are H, and Y¹ and Y² are O) can be prepared by reaction of acids of Formula 2 with amines of Formula 3 in the presence of a dehydrative coupling reagent such as propylphosphonic anhydride, dicyclohexylcarbodiimide, *N*-(3-dimethylaminopropyl)-20 *N*-ethylcarbodiimide, *N,N*-carbonyldiimidazole, 2-chloro-1,3-dimethylimidazolium chloride or 2-chloro-1-methylpyridinium iodide. Polymer-supported reagents, such as polymer-supported cyclohexylcarbodiimide, are also suitable. These reactions are typically run at temperatures ranging from 0 to 60 °C in a solvent such as dichloromethane, acetonitrile, 25 *N,N*-dimethylformamide or ethyl acetate in the presence of a base such as triethylamine, *N,N*-diisopropylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene. See *Organic Process Research & Development* 2009, 13, 900–906 for coupling conditions employing propylphosphonic anhydride. The method of Scheme 1 utilizing propylphosphonic anhydride is illustrated by Step E of Synthesis Example 1. The method of Scheme 1 is illustrated by Step E of Synthesis Example 1 and Step D of Synthesis Example 2.

Scheme 1



As shown in Scheme 2, a compound of Formula **2** can be prepared by reaction of a compound of Formula **2'** with corresponding electrophiles of Formula **18** in the presence of a base. In Formula **18**, G denotes a leaving group, i.e. a nucleofuge. Depending upon selection of R^1 , suitable electrophiles for the reaction can include alkyl halides such as alkyl chlorides, alkyl bromides and alkyl iodides, alkylsulfonates, acid anhydrides such as *tert*-butoxycarbonyl anhydride and acetic anhydride, and haloalkylsilanes such as chlorotrimethylsilane. Suitable bases for the reaction include inorganic bases such as alkali or alkaline earth metal (e.g., lithium, sodium, potassium and cesium) hydroxides, alkoxides, carbonates, and phosphates, and organic bases such as triethylamine, *N,N*-diisopropylethylamine and 1,8-diazabicyclo[5.4.0]undec-7-ene. A wide variety of solvents are suitable for the reaction including, but not limited to, tetrahydrofuran, dichloromethane, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidinone, acetonitrile, C_2 – C_6 alcohols and acetone as well as mixtures of these solvents. This reaction is conducted at temperatures ranging from -20 to 200 $^{\circ}\text{C}$, and typically between 0 and 50 $^{\circ}\text{C}$.


Scheme 2



As shown in Scheme 3, a compound of Formula **2'** can be prepared by hydrolysis of esters of Formula **4**. Hydrolysis is carried out with aqueous base or aqueous acid, typically in the presence of a co-solvent. Suitable bases for the reaction include, but are not limited to, hydroxides such as sodium and potassium hydroxide and carbonates such as sodium and potassium carbonate. Suitable acids for the reaction include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid and sulfuric acid, and organic acids such


as acetic acid and trifluoroacetic acid. A wide variety of co-solvents are suitable for the reaction including, but not limited to, methanol, ethanol and tetrahydrofuran. The reaction is conducted at temperatures ranging from -20°C to the boiling point of the solvent, and typically from 0 to 100°C . The method of Scheme 3 is illustrated by Step D of Synthesis Example 1 and Step D of Synthesis Example 2.

Scheme 3



As shown in Scheme 4, a compound of Formulae **4a** or **4b** can be obtained by reduction of a compound of Formulae **5a** or **5b** respectively and subsequent *in situ* cyclization of the resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro or nitrile group in compounds of Formula **5a** or **5b** are known in the literature. These methods include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel, iron or zinc metal in acidic medium (see, for example, *Berichte der Deutschen Chemischen Gesellschaft* **1904**, 37, 3520–3525), and lithium aluminum hydride. Reduction of an aliphatic nitro group can also be achieved with samarium(II) iodide in the presence of a proton source such as methanol (see for example, *Tetrahedron Letters* **1991**, 32 (14), 1699–1702). Alternatively sodium borohydride in the presence of a nickel catalyst such as nickel(II) acetate or nickel(II) chloride can be used (see for example, *Tetrahedron Letters* **1985**, 26 (52), 6413–6416). The method of Scheme 4 utilizing sodium borohydride in the presence of nickel(II) acetate is illustrated by Step C of Synthesis Example 1. The method of Scheme 4 utilizing iron in the presence of ammonium chloride is illustrated by Step C of Synthesis Example 2.


Scheme 4



As shown in Scheme 5, a compound of Formula **5a** or **5b** can be prepared by reacting diesters of Formula **6** with nitroalkanes of Formula **7a** or nitriles of Formula **7b** respectively, typically in the presence of a base. Suitable bases for the reaction include alkali metal lower alkoxides such as sodium methoxide in methanol or sodium ethoxide in ethanol. Compounds of Formula **6** can readily be prepared by various methods such as by Knoevenagel condensation of aldehydes and malonates (see for example G. Jones, *Organic Reactions* Volume 15, John Wiley and Sons, 1967).


10

Scheme 5




Compounds of Formula **5c** or **5d** (i.e. compounds of Formulae **5a** or **5b** wherein R^2 and R^3 are H) can be prepared by reacting compounds of Formula **8a** or **8b** with malonates of Formula **9** in the presence of a base as shown in Scheme 6. Suitable bases for this reaction include, but are not limited to, alkali metal lower alkoxides such as sodium methoxide in methanol or sodium ethoxide in ethanol, or bases such as lithium

bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide and lithium diisopropylamide in solvents such as tetrahydrofuran. Typically, the reaction is carried out in the range of from –78 °C to 23 °C such as those described in *Synthesis* **2005**, 2239–2245. Conditions for effecting this transformation in refluxing water in the absence of a catalyst are reported in
 5 *Synthetic Communications* **2013**, 43, 744–748.

Scheme 6

A compound of Formula **6** can readily be prepared by Knoevenagel condensation of aldehydes of Formula **14** and malonates of Formula **9** as shown in Scheme 7. Also shown in
 10 Scheme 7, compounds of Formulae **8a** and **8b** can be prepared by Knoevenagel condensation of aldehydes of Formula **14** and nitromethane or acetonitrile respectively.


Scheme 7

Compounds of Formulae **5a'** and **5a''** can be prepared stereoselectively by reacting a
 15 nitroalkene of Formula **8a** with a malonate of Formula **9** in the presence of a chiral catalyst and optionally in the presence of a suitable base as shown in Scheme 8. Suitable catalysts include, but are not limited to Ni(II) with vicinal diamine ligands such as Ni(II) Bis[(*R,R*)-*N,N*'-dibenzylcyclohexane-1,2-diamine]dibromide, Ni(II) Bis[(*S,S*)-*N,N*'-dibenzylcyclohexane-1,2-diamine]dibromide or nickel(II) bromide with chiral
 20 1,1'-bi(tetrahydroisoquinoline) type diamines. Suitable organic bases for this reaction include, but are not limited to, piperidine, morpholine, triethylamine, 4-methylmorpholine or *N,N*-diisopropylethylamine. This transformation can be accomplished neat or in solvents

such as tetrahydrofuran, toluene or dichloromethane. Typically, the reaction is carried out in the range of from -78°C to 80°C using 0 to 1 equivalent of catalyst and optionally 0 to 1 equivalent of a base. Conditions for effecting this transformation have been reported in *J. Am. Chem. Soc.* **2005**, 9958-9959 or *Eur. J. Org. Chem.* **2011**, 5441-5446 for conditions.


5 Nitroalkenes of Formula **8a** can readily be prepared from aldehydes and nitromethane by methods known to those skilled in the art.

Scheme 8




As shown in Scheme 9, compounds of Formulae **1aa** and **1ab** can also be prepared by 10 reductive cyclization of compounds of Formulae **10a** and **10b** analogous to the method of Scheme 4. As also shown in Scheme 9, compounds of Formula **1ba** and **1bb** (i.e. Formula **1** 15 wherein R¹ is OH, R⁴ and R⁵ are H; and Y¹ and Y² are O) can be prepared from compounds of Formulae **10a** and **10b** respectively by catalytic transfer hydrogenation with ammonium formate in the presence of palladium on carbon, and subsequent *in situ* cyclization of the intermediate hydroxylamine. See *J. Med. Chem.* **1993**, 36, 1041-1047 for catalytic transfer hydrogenation/cyclization conditions to produce *N*-hydroxypyrrolidinones.

Scheme 9




As shown in Scheme 10, compounds of Formulae **10a** and **10b** can be prepared by reacting a compound of Formula **11** with a compound of Formula **7a** or a compound of Formula **7b** respectively in a solvent, in the presence of a base analogous to the method described in Scheme 5.

Scheme 10



As shown in Scheme 11, a compound of Formula **10aa** (i.e. Formula **10a** wherein R^{2a} and R^{3a} are H) can be prepared, analogous to the method of Scheme 6, by reacting nitroalkenes of Formula **8** with a malonate of Formula **12**.

Scheme 11




5

As shown in Scheme 12, a compound of Formula **11** can be prepared by reaction of a malonic amide of Formula **12** with an aldehyde of Formula **14**. Also as shown in Scheme 12, a malonic amide of Formula **12** can readily be prepared from lower alkyl malonyl chlorides of Formula **13** such as methyl malonyl chloride and amines of Formula **3**.

10

Scheme 12




15

20


As shown in Scheme 13, mixtures of a compound of Formulae **1c** (i.e. Formula **1** wherein R¹ and R⁵ are H, R⁴ is halogen and Y¹ and Y² are O) and **1d** (i.e. Formula **1** wherein R¹ and R⁴ are H, R⁵ is halogen and Y¹ and Y² are O) can be prepared by reacting compounds of Formula **1a** with a halogen source in a solvent, in the presence or absence of an initiator. Separation of the regioisomers produced in this reaction can be achieved by standard methods such as chromatography or fractional crystallization. Suitable halogen sources for this reaction include bromine, chlorine, *N*-chlorosuccinimide, *N*-bromosuccinimide and *N*-iodosuccinimide. Suitable initiators for this reaction include 2,2'-azobisisobutyronitrile (AIBN) and benzoyl peroxide. Typically, the reaction is carried out in solvents such as dichloromethane in the range of from 0 °C to the boiling point of the solvent.

Scheme 13



As shown in Scheme 14, a compound of Formula **1e** (i.e. Formula **1** wherein R¹ is NH₂, R⁴ and R⁵ are H and Y¹ and Y² are O) can be prepared by reacting compounds of Formula **1a** with an aminating reagent such as *O*-(diphenylphosphinyl)hydroxylamine and hydroxylamino-*O*-sulphonic acid. For procedures, conditions and reagents see *Bioorganic & Medicinal Chemistry Letters* **2009**, *19*, 5924–5926 and *Journal of Organic Chemistry* **2002**, *67*, 6236–6239.


Scheme 14



10


As shown in Scheme 15, a compound of Formula **1f** (i.e. Formula **1** wherein R⁴, R⁵ and R⁶ are H and Y¹ is O) can be produced by reaction of a compound of Formula **15** with an isocyanate (i.e. of Formula **16** wherein Y² is O) or an isothiocyanates (i.e. of Formula **16** wherein Y² is S) in the presence of base. Examples of the base which can be used for the present process include those listed for the method of Scheme 5. The reaction temperature can be selected from the range of from -78 °C to the boiling point of an inert solvent used. Typically, the reaction is carried out at temperatures ranging from -78 °C to 100 °C in a solvent such as toluene.

Scheme 15



As shown in Scheme 16, a compound of Formula **15** can be prepared, analogous to the method described in Scheme 2, by reaction of compounds of Formula **17** with corresponding 5 electrophiles of Formula **18** in the presence of base.


Scheme 16



As shown in Scheme 17, a compound of Formula **17** can be prepared by 10 decarboxylation of an acid of Formula **2**. Decarboxylation is carried by heating a compound of Formula **2** in a solvent, typically in the presence of an acid. Suitable acids for the reaction include, but are not limited to, *p*-toluenesulfonic acid. A wide variety of co-solvents are suitable for the reaction including, but not limited to, toluene, isopropanol acetate and isobutyl methylketone. The reaction is conducted at temperatures ranging from -20 °C and to the boiling point of the solvent, and typically from 0 to 150 °C.

15


Scheme 17



As shown in Scheme 18, a compound of Formula **1g** (i.e. Formula **1** wherein R^1 is H, R^4 and R^5 are H, and Y^1 and Y^2 are S) can be prepared by reacting a compound of Formula **1a** with at least two equivalents of a thionation reagent such as Lawesson's reagent,


tetraphosphorus decasulfide or diphosphorus pentasulfide in a solvent such as tetrahydrofuran or toluene. Typically, the reaction is carried out at temperatures ranging from 0 to 115 °C. One skilled in the art recognizes that using less than two equivalents of the thionating reagent can provide mixtures comprising compounds of Formulae **1g** and **1g'** (products wherein Y¹ is O and Y² is S, or Y¹ is S and Y² is O), which can be separated by conventional methods such as chromatography and crystallization.

Scheme 18



As shown in Scheme 19, a compound of Formula **1h** (i.e. Formula **1** wherein R¹, R⁴, R⁵ are H, Y² is O and Y¹ is NH) can be prepared by alkylation of a compound of Formula **1a** with triethyloxonium tetrafluoroborate (Meerwein's reagent) followed by treatment of the resulting imino ether of Formula **19** with aqueous ammonia.

Scheme 19



15 It is recognized by one skilled in the art that various functional groups can be converted into others to provide different compounds of Formula 1. For a valuable resource that illustrates the interconversion of functional groups in a simple and straightforward fashion, see Larock, R. C., *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*, 2nd Ed., Wiley-VCH, New York, 1999. For example, intermediates 20 for the preparation of compounds of Formula 1 may contain aromatic nitro groups, which can be reduced to amino groups, and then be converted via reactions well known in the art such as the Sandmeyer reaction, to various halides, providing compounds of Formula 1. The above reactions can also in many cases be performed in alternate order.

It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular presented to prepare the compounds of Formula 1.

One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following non-limiting Examples are illustrative of the invention. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. ^1H NMR spectra are reported in ppm downfield from tetramethylsilane; “s” means singlet; and “d” means doublet. Mass spectra (MS) are reported as the molecular weight of the highest isotopic abundance parent ion ($M+1$) formed by addition of H^+ (molecular weight of 1) to the molecule, or ($M-1$) formed by the loss of H^+ (molecular weight of 1) from the molecule, observed by using liquid chromatography coupled to a mass spectrometer (LCMS) using either atmospheric pressure chemical ionization (AP+) where “amu” stands for unified atomic mass units.

SYNTHESIS EXAMPLE 1

Preparation N-(2,3-difluorophenyl)-4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxamide (Compound 13)

Step A: Preparation of 1,3-diethyl 2-[2-(4-fluorophenyl)ethylidene]propanedioate

5 Titanium tetrachloride (14.5 mL, 14.5 mmol, 1 M in methylene chloride) was added dropwise to 20 mL of tetrahydrofuran and cooled to -1.5°C . The temperature was maintained under 3.5°C during dropwise addition. The resulting yellow suspension was slowly combined with a solution of 4-fluorophenyl acetaldehyde (4 g, 29.0 mmol) and diethyl malonate (4.6 g, 29.0 mmol) in 25 mL of dry tetrahydrofuran while maintaining the 10 internal temperature under 3°C . At this point, dry pyridine (9.2 mL, 115.8 mmol) was added to the solution which was then stirred for 1 h maintaining an internal temperature of -3°C to 0°C and then allowing the mixture to warm to ambient temperature over 16 h. The reaction mixture was diluted with water and extracted with ether. The combined organic extracts were washed with water, aqueous 0.5 N HCl, water, aqueous saturated NaHCO_3 and 15 aqueous saturated NaCl sequentially and finally dried over Na_2SO_4 . The crude material was chromatographed on silica gel (60–120 mesh), eluting with 30% ethyl acetate in petroleum ether to give 4.0 g of a crude product of the title compound which was carried on to Step B without characterization or further purification.

Step B: Preparation of 1,3-diethyl 2-[1-(4-fluorophenyl)methyl]-2-nitroethyl]propanedioate

20 To a solution of 1,3-diethyl 2-[2-(4-fluorophenyl)ethylidene]propanedioate (i.e. the product of Step A, 4 g, 14.3 mmol) in ethanol (40 mL) was added nitromethane (8.7 g, 142.7 mmol) followed by sodium ethoxide (0.388 g, 1.4 mmol, 25 wt% in ethanol) and the reaction mixture stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl 25 acetate and washed with water and brine solution. The organic layer was separated and dried over Na_2SO_4 and concentrated in vacuo. The crude material was chromatographed on silica gel (60–120 mesh), eluting with 30% ethyl acetate in petroleum ether to give 5.0 g of a crude product of the title compound which was carried on to Step C without characterization or further purification.

Step C: Preparation of ethyl 4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxylate

30 To a solution of 1,3-diethyl 2-[1-(4-fluorophenyl)methyl]-2-nitroethyl]propanedioate (i.e. the product of Step B, 5.0 g, 14.7 mmol) in ethanol (50 mL) was added $\text{NiAc}_2 \cdot 4\text{H}_2\text{O}$ (18.2 g, 73.2 mmol). The solution was cooled to 0°C and NaBH_4 (2.7 g, 73.2 mmol) was 35 added portion wise. The solution was allowed to warmed to ambient temperature and stirred for 16 h. The reaction mixture was filtered through Celite® diatomaceous earth filter aid. The filtrate was diluted with ethyl acetate and washed with water and brine solution. The

organic layer was separated and then dried over Na_2SO_4 and concentrated in vacuo. The crude material was chromatographed on silica gel (60–120 mesh), eluting with 60% ethyl acetate in petroleum ether to give the title compound as a solid (0.85 g).

MS: [M+1] 266.0.

5 **Step D: Preparation of 4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxylic acid**

To a solution of ethyl 4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxylate (i.e. the product of Step C, 0.8 g, 3.0 mmol) in ethanol (10 mL) at 0 °C was added sodium hydroxide (0.362 g, 50 wt% aq solution). The solution was stirred and allowed to warm to ambient temperature for 16 h. The reaction mass was diluted with ethyl acetate and washed with aqueous 1 N HCl, water and brine solution. The organic layer was separated and then dried over Na_2SO_4 and concentrated in vacuo. The crude material was purified by triturating with diethyl ether and pentane to give the title compound as a solid (0.5 g).

10 MS: [M-1] 236.0.

15 **Step E: Preparation of N-(2,3-difluorophenyl)-4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxamide**

To a solution of 4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxylic acid (i.e. the product of Step D, 0.2 g, 0.84 mmol) in methylene chloride (2 mL) was added triethylamine (0.255 g, 2.5 mmol) and 2,3-difluoroanaline (0.120 g, 0.93 mmol) followed by propylphosphonic anhydride (0.456 g, 1.4 mmol). The solution was stirred for 16 h and then diluted with ethyl acetate, and washed with water and brine solution. The organic layer was separated and then dried over Na_2SO_4 and concentrated in vacuo. The crude material was purified by triturating with diethyl ether and pentane to give the title compound as an off-white solid (0.18 g).

20 MS: [M-1] 236.0 and MP 173–176 °C;

25 ^1H NMR (DMSO- d_6 , 300 MHz) δ 10.06 (s, 1H), 7.97 (s, 1H), 7.61–7.64 (m, 1H), 7.01–7.28 (m, 6H), 3.45–3.48 (m, 1H), 3.25–3.27 (m, 1H), 2.95–3.08 (m, 2H), 2.79–2.81 (m, 2H).

SYNTHESIS EXAMPLE 2

Preparation of N-(2,3-difluorophenyl)-2-oxo-4-[(1E)-2-phenylethenyl]-3-pyrrolidinecarboxamide (Compound 33)

30 **Step A: Preparation of 1,3-diethyl 2-[(2E)-3-phenyl-2-propen-1-ylidene]-propanedioate**

To a solution of (2E)-3-phenyl-2-propenal (5.0 g, 37.83 mmol), diethyl malonate (6.05 g, 37.83 mmol) and piperidine (0.64 g, 7.57 mmol) in toluene (30 mL) was added acetic acid (0.43 mL). The reaction mixture was refluxed for 3 h under a *Dean-Stark* trap to remove water by azeotropic distillation. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers

were washed with water (25 mL), dried over Na_2SO_4 and concentrated to afford the crude product. The crude product was purified by silica gel column chromatography, eluting with 0% to 100% ethyl acetate in petroleum ether, to afford the title compound (8.0 g) as a pale brown liquid.

5 ^1H NMR δ 7.54–7.48 (m, 3H), 7.39–7.34 (m, 3H), 7.29–7.23 (m, 1H), 7.04 (d, J = 15.2 Hz, 1H), 4.37 (q, J = 6.8 Hz, 2H), 4.28 (q, J = 6.8 Hz, 2H), 1.40–1.28 (m, 6H).

Step B: Preparation of 1,3-diethyl 2-[(2E)-1-(nitromethyl)-3-phenyl-2-propen-1-yl]propanedioate

To a solution of 1,3-diethyl 2-[(2E)-3-phenyl-2-propen-1-ylidene]-propanedioate (i.e. the product of Step A, 6.0 g, 21.87 mmol) and nitromethane (2.0 g, 32.80 mmol) in ethanol (60 mL) at 0 °C was added sodium methoxide (120 mg, 2.18 mmol). The reaction mixture was stirred at 23 °C overnight. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction was concentrated under reduced pressure, and the crude reaction mass was extracted with ethyl acetate (3 × 40 mL). The organic layer was washed with water (50 mL), dried over Na_2SO_4 and concentrated to afford the crude product. The crude product was purified by column chromatography, eluting with 0% to 100% ethyl acetate in petroleum ether, to afford the title compound (3.9 g) as a pale yellow solid.

10 ^1H NMR δ 7.33–7.24 (m, 5H), 6.57 (d, J = 16.0 Hz, 1H), 6.15–6.08 (m, 1H), 4.77–4.66 (m, 2H), 4.25–4.16 (m, 4H), 3.75–3.72 (m, 1H), 3.66 (d, J = 7.2 Hz, 1H), 1.29–1.20 (m, 6H).

Step C: Preparation of ethyl 2-oxo-4-[(1E)-2-phenylethethyl]-3-pyrrolidinecarboxylate

A mixture of 1,3-diethyl 2-[(2E)-1-(nitromethyl)-3-phenyl-2-propen-1-yl]propanedioate (i.e. the product of Step B, 3.9 g, 11.62 mmol), iron powder (3.25 g, 58.15 mmol) and ammonium chloride (310 mg, 5.81 mmol) in a mixture of ethanol and water (9:1, 60 mL) was heated to the reflux temperature of the solvent for 24 h. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography, eluting with 0% to 100% ethyl acetate in petroleum ether, to afford the title compound (1.5 g) as a pale yellow liquid.

20 ^1H NMR δ 7.36–7.23 (m, 5H), 6.54 (d, J = 15.6 Hz, 1H), 6.18–6.12 (m, 1H), 5.94 (brs, 1H), 4.26 (q, J = 6.8 Hz, 2H), 3.73–3.63 (m, 2H), 3.32 (d, J = 8.8 Hz, 1H), 3.25 (t, J = 8.4 Hz, 1H), 1.31 (t, J = 6.8 Hz, 3H).

Step D: Preparation of *N*-(2,3-difluorophenyl)-2-oxo-4-[(1*E*)-2-phenylethenyl]-3-pyrrolidinecarboxamide

To a solution of 2-oxo-4-[(1*E*)-2-phenylethenyl]-3-pyrrolidinecarboxylate (i.e. the product of Step C, 1.5 g, 5.78 mmol) in a mixture of methanol and tetrahydrofuran (6:4, 20 mL) was added 1 N aqueous sodium hydroxide. The reaction mixture was stirred at 23 °C for 16 h. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction mixture was cooled to 0 °C, acidified with 1 N hydrochloric acid and extracted with ethyl acetate (3 × 25 mL). The organic layer was washed with water (20 mL), dried over Na₂SO₄ and concentrated to afford the intermediate acid (1.12 g), which was used directly in the amine coupling step without any further purification. To a solution of the intermediate acid (0.6 g, 2.59 mmol), 2,3-difluoroaniline (0.4 g, 3.11 mmol) and triethylamine (1.09 mL, 7.78 mmol) in methylene chloride (20 mL) at 0 °C was added propylphosphonic anhydride (T3P®) (1.24 g, 3.89 mmol). The reaction mixture was stirred at 23 °C overnight. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction mixture was poured into water (15 mL) and extracted with dichloromethane (3 × 15 mL). The organic layer was separated, dried over Na₂SO₄ and concentrated under reduced pressure to afford crude product. The crude compound was purified by column chromatography, eluting with 0% to 100% ethyl acetate in petroleum ether, to afford the title compound, a compound of the present invention, as an off-white solid (0.5 g).

¹H NMR (DMSO-d₆) δ 10.23 (s, 1H), 8.10 (s, 1H), 7.80–7.76 (m, 1H), 7.41 (d, *J* = 7.6 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.24–7.15 (m, 3H), 6.52 (d, *J* = 16 Hz, 1H), 6.40–6.34 (m, 1H), 3.67 (d, *J* = 9.6 Hz, 1H), 3.60–3.56 (m, 1H), 3.49 (t, *J* = 8.8 Hz, 1H), 3.17 (t, *J* = 8.8 Hz, 1H).

25 SYNTHESES EXAMPLE 3

Preparation of *N*-(2,3-difluorophenyl)-2-oxo-4-(2-phenylethyl)-3-pyrrolidinecarboxamide
(Compound 35)

Step A: Preparation of *N*-(2,3-difluorophenyl)-2-oxo-4-(2-phenylethyl)pyrrolidine-3-carboxamide

30 A solution of *N*-(2,3-difluorophenyl)-2-oxo-4-[(1*E*)-2-phenylethenyl]-3-pyrrolidinecarboxamide (i.e. the product of Example 2, Step D, 0.30 g, 0.87 mmol) in ethanol (20 mL) was placed under nitrogen atmosphere. Palladium on carbon (10%, 0.150 g) was added, and the reaction mixture was stirred under hydrogen balloon pressure at 23 °C for 2 h. The progress of the reaction was monitored by thin-layer chromatography analysis. After completion, the reaction mixture was filtered through Celite® diatomaceous earth filter aid, and the filtrate was concentrated under reduced pressure to afford the crude product. The crude product was purified by silica gel column chromatography, eluting with

0% to 100% ethyl acetate in petroleum ether, to afford the title compound, a compound of the invention, as a colorless solid (0.20 g).

¹H NMR (DMSO-d₆) δ 10.24 (s, 1H), 7.98 (s, 1H), 7.79–7.76 (m, 1H), 7.29–7.16 (m, 7H), 3.46–3.39 (m, 2H), 2.94 (t, *J* = 8.8 Hz, 1H), 2.77–2.71 (m, 1H), 2.59 (t, *J* = 8.0 Hz, 2H), 5 1.86–1.74 (m, 2H).

SYNTHESIS EXAMPLE 4

Preparation of 4-[2-(3-chlorophenyl)ethynyl]N-(2-fluorophenyl)-2-oxo-3-pyrrolidinecarboxamide (Compound 25)

Step A: Preparation of 3-(3-chlorophenyl)-2-propynal

10 Step B: Preparation of 1,3-diethyl 2-[3-(3-chlorophenyl)-2-propyn-1-ylidene]propanedioate

Step C: Preparation of 1,3-diethyl 2-[3-(3-chlorophenyl)-1-(nitromethyl)-2-propyn-1-yl]propanedioate


Step D Preparation of ethyl 4-[2-(3-chlorophenyl)ethynyl]-2-oxo-3-pyrrolidinecarboxylate

Step E: Preparation of 4-[2-(3-chlorophenyl)ethynyl]-2-oxo-3-pyrrolidinecarboxylic acid

15 Step F: Preparation of 4-[2-(3-chlorophenyl)ethynyl]-N-(2-fluorophenyl)-2-oxo-3-pyrrolidinecarboxamide

By the procedures described herein together with methods known in the art, the following compounds of Tables 1 to 320 can be prepared. The following abbreviations are used in the Tables which follow: *i* means iso, *c* means cyclo, Me means methyl, Et means ethyl, Pr means propyl, Bu means butyl, *i*-Pr means isopropyl, *c*-Pr cyclopropyl, Ph means phenyl, OMe means methoxy, SMe means methylthio, NHMe means methylamino, CN means cyano, NO₂ means nitro, TMS means trimethylsilyl, SOMe means methylsulfinyl, C₂F₅ means CF₂CF₃ and SO₂Me means methylsulfonyl.

Table 1



25

J = -CH₂-; R¹ = H; Q² = Ph(2-F); and Q¹ =

Q ¹	Q ¹	Q ¹
Ph(3-Cl)	Ph(3-Et)	Ph(3-OCF ₂ H)
Ph(3-F)	Ph(3-CF ₃)	Ph(3-O- <i>i</i> -Pr)
Ph(3-Br)	Ph(3-CH ₂ CF ₃)	Ph(3-OMe)
Ph(3-Me)	Ph(3-OCF ₃)	Ph(3-OCF ₂ CF ₂ H)

Q ¹	Q ¹	Q ¹
Ph(2-Cl)	2-Pyridinyl(6-CF ₃)	2-Thienyl
Ph(2-F)	2-Pyridinyl(6-Me)	2-Thienyl(4-CF ₃)
Ph(2-Br)	2-Pyridinyl(5-F)	2-Thienyl(5-CF ₃)
Ph(2-Me)	2-Pyridinyl(5-CF ₃)	3-Thienyl
Ph(2-CF ₃)	2-Pyridinyl(5-Me)	3-Thienyl(4-CF ₃)
Ph(2-OCF ₃)	2-Pyridinyl(4-F)	3-Thienyl(5-CF ₃)
Ph(2-OCF ₂ H)	2-Pyridinyl(4-CF ₃)	2-Furyl
Ph(2-OMe)	2-Pyridinyl(4-Me)	2-Furyl(4-CF ₃)
Ph(2-OCF ₂ CF ₂ H)	2-Pyridinyl(3-F)	2-Furyl(5-CF ₃)
Ph(2-CH ₂ CF ₃)	2-Pyridinyl(3-CF ₃)	3-Furyl
Ph(2-O- <i>i</i> -Pr)	2-Pyridinyl(3-Me)	3-Furyl(4-CF ₃)
Ph(4-Cl)	3-Pyridinyl	3-Furyl(5-CF ₃)
Ph(4-F)	3-Pyridinyl(6-F)	1 <i>H</i> -Pyrazol-1-yl
Ph(4-Br)	3-Pyridinyl(6-CF ₃)	4-CF ₃ -1 <i>H</i> -Pyrazol-1-yl
Ph(4-Me)	3-Pyridinyl(6-Me)	1 <i>H</i> -Imidazol-1-yl
Ph(4-Et)	3-Pyridinyl(5-F)	4-CF ₃ -1 <i>H</i> -Imidazol-1-yl
Ph(4-CF ₃)	3-Pyridinyl(5-CF ₃)	2-CF ₃ -1 <i>H</i> -Imidazol-1-yl
Ph(4-OCF ₃)	3-Pyridinyl(5-Me)	1-Me-1 <i>H</i> -Imidazol-2-yl
Ph(4-OCF ₂ H)	3-Pyridinyl(4-F)	1-Me-1 <i>H</i> -Imidazol-4-yl
Ph(4-OMe)	3-Pyridinyl(4-CF ₃)	3-Me-1 <i>H</i> -Imidazol-4-yl
Ph(4-CH ₂ CF ₃)	3-Pyridinyl(4-Me)	1-Me-1 <i>H</i> -Pyrazol-4-yl
Ph(4-O- <i>i</i> -Pr)	3-Pyridinyl(2-F)	1-Me-1 <i>H</i> -1,2,3-Triazol-4-yl
Ph(4-OCF ₂ CF ₂ H)	3-Pyridinyl(2-CF ₃)	2-Me-1 <i>H</i> -1,2,3-Triazol-4-yl
Ph(2,3-di-F)	3-Pyridinyl(2-Me)	4-Me-1 <i>H</i> -1,2,3-Triazol-2-yl
Ph(2,4-di-F)	4-Pyridinyl	4-Me-1 <i>H</i> -1,2,3-Triazol-1-yl
Ph(2,5-di-F)	4-Pyridinyl(6-F)	Pyrazin-2-yl
Ph(2,6-di-F)	4-Pyridinyl(6-CF ₃)	Pyrazin-2-yl(5-CF ₃)
Ph(3,4-di-F)	4-Pyridinyl(6-Me)	Pyrimidin-2-yl
Ph(3,5-di-F)	4-Pyridinyl(5-F)	Pyrimidin-2-yl(5-CF ₃)
Ph(3-Me,4-F)	4-Pyridinyl(5-CF ₃)	Pyrimidin-5-yl
Ph(3-F,4-Me)	4-Pyridinyl(5-Me)	Pyrimidin-5-yl(2-CF ₃)
Ph(3-CF ₃ ,4-F)	4-Pyridinyl(3-F)	1,3,5-Triazin-2-yl
Ph(3-F,4-CF ₃)	4-Pyridinyl(3-CF ₃)	Thiazol-2-yl
Ph(2,3,4-tri-F)	4-Pyridinyl(3-Me)	Thiazol-2-yl(5-CF ₃)
Ph(3,4,5-tri-F)	4-Pyridinyl(2-F)	Thiazol-5-yl
2-Pyridinyl	4-Pyridinyl(2-CF ₃)	Thiazol-5-yl(2-CF ₃)
2-Pyridinyl(6-F)	4-Pyridinyl(2-Me)	Oxazol-2-yl

Q ¹	Q ¹	Q ¹
Oxazol-2-yl(5-CF ₃)	1,4-Dioxolan-2-yl	Ph(3-SCF ₃)
Oxazol-5-yl	1,4-Dithiolan-2-yl	Ph(3-S- <i>c</i> -Pr)
Oxazol-5-yl(2-CF ₃)	1-naphthyl	Ph(3-SOMe)
Isothiazol-5-yl	2-naphthyl	Ph(3-SOCF ₃)
Isothiazol-5-yl(3-CF ₃)	Benzofuran-2-yl	Ph(3-SO- <i>c</i> -Pr)
Isothiazol-3-yl	Benzothiophen-2-yl	Ph(3-SO ₂ Me)
Isothiazol-3-yl(5-CF ₃)	1,3-Benzoxazol-2-yl	Ph(3-SO ₂ CF ₃)
Isoxazol-5-yl	1,3-Benzothiazol-2-yl	Ph(3-SO ₂ - <i>c</i> -Pr)
Isoxazol-5-yl(3-CF ₃)	7-Quinolinyl	Ph(3-propargyl)
Isoxazol-3-yl	Indazol-1-yl	Ph(3-(2-Butynyl))
Isoxazol-3-yl(5-CF ₃)	Benzimidazol-1-yl	Ph(2-CH ₂ CH ₂ OCH ₂ CH ₃)
1 <i>H</i> -1,2,3,4-Tetrazol-1-yl	Indol-1-yl	Ph(2-CF ₃)
5-Me-1 <i>H</i> -1,2,3,4-Tetrazol-1-yl	Pyrrolo[2,3- <i>c</i>]pyridin-1-yl	Ph(3-CF ₃)
1-Me-1 <i>H</i> -1,2,3,4-Tetrazol-5-yl	Ph(3-OCH ₂ - <i>c</i> -Pr)	Ph(2-C(=O)CH ₃)
1 <i>H</i> -1,2,4-Triazol-1-yl	Ph(2-OCH ₂ - <i>c</i> -Pr)	Ph(2-OC(=O)CH ₃)
1,3,4-Oxadiazol-2-yl	Ph(4-O(CH ₂) ₄ - <i>c</i> -hex)	Ph(3-OC(=O)CH ₃)
1,3,4-Thiadiazol-2-yl	Ph(CH ₂ - <i>c</i> -Pr)	Ph(2-OC(=O)CF ₃)
1,2,4-Oxadiazol-3-yl	Ph(4-(CH ₂) ₄ - <i>c</i> -hex)	Ph(3-OC(=O)CF ₃)
1,2,4-Thiadiazol-3-yl	Ph(3-OCH ₂ CF ₂))	
Tetrahydropyran-2-yl	Ph(2-(3,3-dichloroallyloxy))	
Tetrahydropyran-3-yl	Ph(2-methoxyethoxy)	
Tetrahydrofuran-2-yl	Ph(3-propoxypropoxy)	
Tetrahydrofuran-3-yl	Ph(2-CH ₂ CH ₂ SCH ₃)	
1,3-Dioxolan-4-yl	Ph(2-CH ₂ CH ₂ SOCH ₃)	
2,2-di-F-1,3-Dioxolan-4-yl	Ph(2-CH ₂ CH ₂ SO ₂ CH ₃)	
1,3-Dithiolan-4-yl	Ph(3-SMe)	


Table 2 is constructed in the same manner except that the Row Heading “J = -CH₂-; R¹ = H; Q² = Ph(2-F); and Q¹ =” is replaced with the Row Heading listed for Table 2 below (i.e. “J = -CH₂-; R¹ = H; Q² = Ph(2,3-di-F); and Q¹ =”). Therefore the first entry in Table 2 is a compound of Formula 1 wherein J is -CH₂-; R¹ is H; Q² is Ph(2,3-di-F); and Q¹ is Ph(3-Cl) (i.e. 3-chlorophenyl). Tables 3 through 40 are constructed similarly.

Table	Row Heading
2	J = -CH ₂ -; R ¹ = H; Q ² = Ph(2,3-di-F); and Q ¹ =
3	J = -CH ₂ -; R ¹ = H; Q ² = Ph(2,4-di-F); and Q ¹ =
4	J = -CH ₂ -; R ¹ = H; Q ² = Ph(2,3,4-tri-F); and Q ¹ =
5	J = -CH ₂ -; R ¹ = H; Q ² = Ph(2-CF ₃); and Q ¹ =

6	$J = -\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-Me)}$; and $Q^1 =$
7	$J = -\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-NO}_2\text{)}$; and $Q^1 =$
8	$J = -\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-Cl)}$; and $Q^1 =$
9	$J = -\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-SO}_2\text{Me)}$; and $Q^1 =$
10	$J = -\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-F,3-Cl)}$; and $Q^1 =$
11	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-F)}$; and $Q^1 =$
12	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2,3-di-F)}$; and $Q^1 =$
13	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2,4-di-F)}$; and $Q^1 =$
14	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2,3,4-tri-F)}$; and $Q^1 =$
15	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-CF}_3\text{)}$; and $Q^1 =$
16	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-Me)}$; and $Q^1 =$
17	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-NO}_2\text{)}$; and $Q^1 =$
18	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-Cl)}$; and $Q^1 =$
19	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-SO}_2\text{Me)}$; and $Q^1 =$
20	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{H}$; $Q^2 = \text{Ph(2-F,3-Cl)}$; and $Q^1 =$
21	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-F)}$; and $Q^1 =$
22	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,3-di-F)}$; and $Q^1 =$
23	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,4-di-F)}$; and $Q^1 =$
24	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,3,4-tri-F)}$; and $Q^1 =$
25	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-CF}_3\text{)}$; and $Q^1 =$
26	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-Me)}$; and $Q^1 =$
27	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-NO}_2\text{)}$; and $Q^1 =$
28	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-Cl)}$; and $Q^1 =$
29	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-SO}_2\text{Me)}$; and $Q^1 =$
30	$J = -\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-F,3-Cl)}$; and $Q^1 =$
31	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-F)}$; and $Q^1 =$
32	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,3-di-F)}$; and $Q^1 =$
33	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,4-di-F)}$; and $Q^1 =$
34	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2,3,4-tri-F)}$; and $Q^1 =$
35	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-CF}_3\text{)}$; and $Q^1 =$
36	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-Me)}$; and $Q^1 =$
37	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-NO}_2\text{)}$; and $Q^1 =$
38	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-Cl)}$; and $Q^1 =$
39	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-SO}_2\text{Me)}$; and $Q^1 =$
40	$J = -\text{CH}_2\text{CH}_2-$; $R^1 = \text{Me}$; $Q^2 = \text{Ph(2-F,3-Cl)}$; and $Q^1 =$

Table 41

Table 41 is constructed the same way as Table 1 above, except the structure is replaced with the following:




5

Tables 42 through 80

This disclosure also includes Tables 42 through 80, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 41 above.

Table 81


10 Table 81 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 82 through 120

15 This disclosure also includes Tables 82 through 120, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 81 above.

Table 121

Table 121 is constructed the same way as Table 1 above, except the structure is replaced with the following:




Tables 122 through 160

This disclosure also includes Tables 122 through 160, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 121 above.

5

Table 161


Table 161 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 162 through 200

10 This disclosure also includes Tables 162 through 200, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 161 above.

Table 201


15 Table 201 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 202 through 240

20 This disclosure also includes Tables 202 through 240, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 201 above.

Table 241

Table 241 is constructed the same way as Table 1 above, except the structure is replaced with the following:




5

Tables 242 through 280

This disclosure also includes Tables 242 through 280, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 241 above.

Table 281

10 Table 281 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 282 through 320

15 This disclosure also includes Tables 282 through 320, each Table is constructed in the same fashion as Tables 2 through 40 above, except that the structure is replaced with the structure in Table 281 above.

Formulation/Utility

20 A compound of this invention will generally be used as a herbicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.

25 Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil in water emulsions, flowable concentrates and/or suspoemulsions) and

the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil in water emulsion, flowable concentrate and suspo emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water dispersible (“wettable”) or water soluble. Films and coatings formed from film forming solutions or flowable suspensions are particularly useful for seed treatment. Active 10 ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or “overcoated”). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High strength compositions are primarily used 15 as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water, but occasionally another suitable medium like an aromatic or paraffinic hydrocarbon or vegetable oil. Spray volumes can range from about one to several thousand liters per hectare, but more typically are in the range from about ten to 20 several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting.

25 The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.

Weight Percent			
	<u>Active Ingredient</u>	<u>Diluent</u>	<u>Surfactant</u>
Water Dispersible and Water soluble Granules, Tablets and Powders	0.001–90	0–99.999	0–15
Oil Dispersions, Suspensions, Emulsions, Solutions (including Emulsifiable Concentrates)	1–50	40–99	0–50
Dusts	1–25	70–99	0–5
Granules and Pellets	0.001–99	5–99.999	0–15
High Strength Compositions	90–99	0–10	0–2

Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described 5 in Watkins et al., *Handbook of Insecticide Dust Diluents and Carriers*, 2nd Ed., Dorland Books, Caldwell, New Jersey.

Liquid diluents include, for example, water, *N,N*-dimethylalkanamides (e.g., *N,N*-dimethylformamide), limonene, dimethyl sulfoxide, *N*-alkylpyrrolidones (e.g., *N*-methylpyrrolidinone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene 10 glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkynaphthalenes, glycerine, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkynaphthalenes, ketones such as 15 cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and γ -butyrolactone, and alcohols, which can be linear, branched, 20 saturated or unsaturated, such as methanol, ethanol, *n*-propanol, isopropyl alcohol, *n*-butanol, isobutyl alcohol, *n*-hexanol, 2-ethylhexanol, *n*-octanol, decanol, isodecyl alcohol, isoctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also 25 include glycerol esters of saturated and unsaturated fatty acids (typically C₆–C₂₂), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of 30 glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, *Solvents Guide*, 2nd Ed., Interscience, New York, 1950.

The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as “surface active agents”) generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be 35 useful as wetting agents, dispersants, emulsifiers or defoaming agents.

Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or

linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from 5 ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric 10 surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene 15 glycol fatty acid esters; silicone based surfactants; and sugar derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.

Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; 20 lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated 25 alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as *N,N*-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides and ethoxylated 30 amides; amines such as *N*-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary 35 ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including *McCutcheon's Emulsifiers and Detergents*, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, *Encyclopedia of Surface Active Agents*, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, *Synthetic Detergents*, Seventh Edition, John Wiley and Sons, New York, 1987.

Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in *McCutcheon's Volume 2: Functional Materials*, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.

The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm . Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", *Chemical Engineering*, December 4, 1967, pp 147-48, *Perry's Chemical Engineer's Handbook*, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following,

and WO 91/13546. Pellets can be prepared as described in U.S. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 5 3,299,566.

For further information regarding the art of formulation, see T. S. Woods, "The Formulator's Toolbox – Product Forms for Modern Agriculture" in *Pesticide Chemistry and Bioscience, The Food–Environment Challenge*, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120–133. See also U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10–41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138–140, 162–164, 166, 167 and 169–182; U.S. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1–4; Klingman, *Weed Control as a Science*, John Wiley and Sons, Inc., New York, 1961, pp 81–96; Hance et al., *Weed Control Handbook*, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and *Developments in formulation technology*, PJB Publications, Richmond, UK, 2000.

In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Table A. Without further elaboration, it is believed that one skilled in the art using the preceding 20 description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except where otherwise indicated.

Example A

High Strength Concentrate

Compound 1	98.5%
silica aerogel	0.5%
synthetic amorphous fine silica	1.0%

Example B

Wettable Powder

Compound 1	65.0%
Dodecylphenol-polyethylene glycol ether	2.0%
sodium ligninsulfonate	4.0%
sodium silicoaluminate	6.0%
montmorillonite (calcined)	23.0%

Example C

Granule

Compound 1	10.0%
------------	-------

attapulgite granules (low volatile matter, 0.71/0.30 mm; 90.0%
U.S.S. No. 25–50 sieves)

Example D

Extruded Pellet

Compound 1	25.0%
anhydrous sodium sulfate	10.0%
crude calcium ligninsulfonate	5.0%
sodium alkylnaphthalenesulfonate	1.0%
calcium/magnesium bentonite	59.0%

Example E

Emulsifiable Concentrate

Compound 1	10.0%
polyoxyethylene sorbitol hexoleate	20.0%
C ₆ –C ₁₀ fatty acid methyl ester	70.0%

Example F

Microemulsion

Compound 1	5.0%
polyvinylpyrrolidone-vinyl acetate copolymer	30.0%
alkylpolyglycoside	30.0%
glyceryl monooleate	15.0%
water	20.0%

Example G

Suspension Concentrate

Compound 1	35%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
water	53.7%

Example H

Emulsion in Water

Compound 1	10.0%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%

xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
aromatic petroleum based hydrocarbon	20.0
Water	58.7%

Example I

Oil Dispersion

Compound 1	25%
polyoxyethylene sorbitol hexaoleate	15%
organically modified bentonite clay	2.5%
fatty acid methyl ester	57.5%

The present disclosure also includes Formulation Examples A through I above except “Compound 1” in each of the above Examples A through I is replaced with “Compound 2”, “Compound 3”, “Compound 4”, “Compound 5”, “Compound 7”, “Compound 8”, 5 “Compound 9”, “Compound 10”, “Compound 11”, “Compound 12”, “Compound 13”, “Compound 14”, “Compound 15”, “Compound 16”, “Compound 17”, “Compound 18”, “Compound 19”, “Compound 20”, “Compound 21”, “Compound 22”, “Compound 23”, “Compound 24”, “Compound 25”, “Compound 26”, “Compound 27” “Compound 28” “Compound 29”, “Compound 30”, “Compound 31”, “Compound 32”, “Compound 33” 10 “Compound 34” or “Compound 35”.

Test results indicate that the compounds of the present invention are highly active preemergent and/or postemergent herbicides and/or plant growth regulators. The compounds of the invention generally show highest activity for postemergence weed control (i.e. applied after weed seedlings emerge from the soil) and preemergence weed control (i.e. applied 15 before weed seedlings emerge from the soil). Many of them have utility for broad-spectrum pre- and/or postemergence weed control in areas where complete control of all vegetation is desired such as around fuel storage tanks, industrial storage areas, parking lots, drive-in theaters, air fields, river banks, irrigation and other waterways, around billboards and highway and railroad structures. Many of the compounds of this invention, by virtue of 20 selective metabolism in crops versus weeds, or by selective activity at the locus of physiological inhibition in crops and weeds, or by selective placement on or within the environment of a mixture of crops and weeds, are useful for the selective control of grass and broadleaf weeds within a crop/weed mixture. One skilled in the art will recognize that 25 the preferred combination of these selectivity factors within a compound or group of compounds can readily be determined by performing routine biological and/or biochemical assays. Compounds of this invention may show tolerance to important agronomic crops

including, but is not limited to, alfalfa, barley, cotton, wheat, rape, sugar beets, corn (maize), sorghum, soybeans, rice, oats, peanuts, vegetables, tomato, potato, perennial plantation crops including coffee, cocoa, oil palm, rubber, sugarcane, citrus, grapes, fruit trees, nut trees, banana, plantain, pineapple, hops, tea and forests such as eucalyptus and conifers (e.g., 5 loblolly pine), and turf species (e.g., Kentucky bluegrass, St. Augustine grass, Kentucky fescue and Bermuda grass). Compounds of this invention can be used in crops genetically transformed or bred to incorporate resistance to herbicides, express proteins toxic to invertebrate pests (such as *Bacillus thuringiensis* toxin), and/or express other useful traits. Those skilled in the art will appreciate that not all compounds are equally effective against 10 all weeds. Alternatively, the subject compounds are useful to modify plant growth.

As the compounds of the invention have (both preemergent and postemergent herbicidal) activity, to control undesired vegetation by killing or injuring the vegetation or reducing its growth, the compounds can be usefully applied by a variety of methods involving contacting a herbicidally effective amount of a compound of the invention, or a 15 composition comprising said compound and at least one of a surfactant, a solid diluent or a liquid diluent, to the foliage or other part of the undesired vegetation or to the environment of the undesired vegetation such as the soil or water in which the undesired vegetation is growing or which surrounds the seed or other propagule of the undesired vegetation.

A herbicidally effective amount of the compounds of this invention is determined by a 20 number of factors. These factors include: formulation selected, method of application, amount and type of vegetation present, growing conditions, etc. In general, a herbicidally effective amount of compounds of this invention is about 0.001 to 20 kg/ha with a preferred range of about 0.004 to 1 kg/ha. One skilled in the art can easily determine the herbicidally effective amount necessary for the desired level of weed control.

25 In one common embodiment, a compound of the invention is applied, typically in a formulated composition, to a locus comprising desired vegetation (e.g., crops) and undesired vegetation (i.e. weeds), both of which may be seeds, seedlings and/or larger plants, in contact with a growth medium (e.g., soil). In this locus, a composition comprising a compound of the invention can be directly applied to a plant or a part thereof, particularly of 30 the undesired vegetation, and/or to the growth medium in contact with the plant.

Plant varieties and cultivars of the desired vegetation in the locus treated with a compound of the invention can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants (transgenic plants) are those in which a heterologous gene (transgene) has been stably integrated into the plant's 35 genome. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Genetically modified plant cultivars in the locus which can be treated according to the invention include those that are resistant against one or more biotic stresses (pests such as

nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, cold temperature, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits of, for example, herbicide tolerance, insect resistance, modified oil profiles or drought tolerance. Useful genetically modified plants containing single gene transformation events or combinations of transformation events are listed in Exhibit C. Additional information for the genetic modifications listed in Exhibit C can be obtained from publicly available databases maintained, for example, by the U.S. Department of Agriculture.

The following abbreviations, T1 through T37, are used in Exhibit C for traits. A “-“ means the entry is not available; “tol.” means “tolerance” and “res.” means resistance.

Trait	Description	Trait	Description	Trait	Description
T1	Glyphosate tol.	T15	Cold tol.	T27	High tryptophan
T2	High lauric acid oil	T16	Imidazolinone herb. tol.	T28	Erect leaves semidwarf
T3	Glufosinate tol.	T17	Modified alpha-amylase	T29	Semidwarf
T4	Phytate breakdown	T18	Pollination control	T30	Low iron tol.
T5	Oxynil tol.	T19	2,4-D tol.	T31	Modified oil/fatty acid
T6	Disease res.	T20	Increased lysine	T32	HPPD tol.
T7	Insect res.	T21	Drought tol.	T33	High oil
T9	Modified flower color	T22	Delayed ripening/senescence	T34	Aryloxyalkanoate tol.
T11	ALS Herbicide tol.	T23	Modified product quality	T35	Mesotrione tol.
T12	Dicamba tol.	T24	High cellulose	T36	Reduced nicotine
T13	Anti-allergy	T25	Modified starch/carbohydrate	T37	Modified product
T14	Salt tol.	T26	Insect & disease resist.		

Exhibit C

Crop	Event Name	Event Code	Trait(s)	Gene(s)
Alfalfa	J101	MON-00101-8	T1	cp4 epsps (aroA:CP4)
Alfalfa	J163	MON-00163-7	T1	cp4 epsps (aroA:CP4)
Canola*	23-18-17 (Event 18)	CGN-89465-2	T2	te
Canola*	23-198 (Event 23)	CGN-89465-2	T2	te
Canola*	61061	DP-061061-7	T1	gat4621
Canola*	73496	DP-073496-4	T1	gat4621
Canola*	GT200 (RT200)	MON-89249-2	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	GT73 (RT73)	MON-00073-7	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	HCN10 (Topas 19/2)	-	T3	bar
Canola*	HCN28 (T45)	ACS-BN008-2	T3	pat (syn)
Canola*	HCN92 (Topas 19/2)	ACS-BN007-1	T3	bar

Canola*	MON88302	MON-88302-9	T1	cp4 epsps (aroA:CP4)
Canola*	MPS961	-	T4	phyA
Canola*	MPS962	-	T4	phyA
Canola*	MPS963	-	T4	phyA
Canola*	MPS964	-	T4	phyA
Canola*	MPS965	-	T4	phyA
Canola*	MS1 (B91-4)	ACS-BN004-7	T3	bar
Canola*	MS8	ACS-BN005-8	T3	bar
Canola*	OXY-235	ACS-BN011-5	T5	bxn
Canola*	PHY14	-	T3	bar
Canola*	PHY23	-	T3	bar
Canola*	PHY35	-	T3	bar
Canola*	PHY36	-	T3	bar
Canola*	RF1 (B93-101)	ACS-BN001-4	T3	bar
Canola*	RF2 (B94-2)	ACS-BN002-5	T3	bar
Canola*	RF3	ACS-BN003-6	T3	bar
Bean	EMBRAPA 5.1	EMB-PV051-1	T6	acl (sense and antisense)
Brinjal #	EE-1	-	T7	cry1Ac
Cotton	19-51a	DD-Ø1951A-7	T11	S4-HrA
Cotton	281-24-236	DAS-24236-5	T3,T7	pat (syn); cry1F
Cotton	3006-210-23	DAS-21Ø23-5	T3,T7	pat (syn); cry1Ac
Cotton	31707	-	T5,T7	bxn; cry1Ac
Cotton	31803	-	T5,T7	bxn; cry1Ac
Cotton	31807	-	T5,T7	bxn; cry1Ac
Cotton	31808	-	T5,T7	bxn; cry1Ac
Cotton	42317	-	T5,T7	bxn; cry1Ac
Cotton	BNLA-601	-	T7	cry1Ac
Cotton	BXN10211	BXN10211-9	T5	bxn; cry1Ac
Cotton	BXN10215	BXN10215-4	T5	bxn; cry1Ac
Cotton	BXN10222	BXN10222-2	T5	bxn; cry1Ac
Cotton	BXN10224	BXN10224-4	T5	bxn; cry1Ac
Cotton	COT102	SYN-IR102-7	T7	vip3A(a)
Cotton	COT67B	SYN-IR67B-1	T7	cry1Ab
Cotton	COT202	-	T7	vip3A
Cotton	Event 1	-	T7	cry1Ac
Cotton	GMF Cry1A	GTL-GMF311-7	T7	cry1Ab-Ac
Cotton	GHB119	BCS-GH005-8	T7	cry2Ae
Cotton	GHB614	BCS-GH002-5	T1	2mepsps

Cotton	GK12	-	T7	cry1Ab-Ac
Cotton	LLCotton25	ACS-GH001-3	T3	bar
Cotton	MLS 9124	-	T7	cry1C
Cotton	MON1076	MON-89924-2	T7	cry1Ac
Cotton	MON1445	MON-01445-2	T1	cp4 epsps (aroA:CP4)
Cotton	MON15985	MON-15985-7	T7	cry1Ac; cry2Ab2
Cotton	MON1698	MON-89383-1	T7	cp4 epsps (aroA:CP4)
Cotton	MON531	MON-00531-6	T7	cry1Ac
Cotton	MON757	MON-00757-7	T7	cry1Ac
Cotton	MON88913	MON-88913-8	T1	cp4 epsps (aroA:CP4)
Cotton	Nqwe Chi 6 Bt	-	T7	-
Cotton	SKG321	-	T7	cry1A; CpTI
Cotton	T303-3	BCS-GH003-6	T3,T7	cry1Ab; bar
Cotton	T304-40	BCS-GH004-7	T3,T7	cry1Ab; bar
Cotton	CE43-67B	-	T7	cry1Ab
Cotton	CE46-02A	-	T7	cry1Ab
Cotton	CE44-69D	-	T7	cry1Ab
Cotton	1143-14A	-	T7	cry1Ab
Cotton	1143-51B	-	T7	cry1Ab
Cotton	T342-142	-	T7	cry1Ab
Cotton	PV-GHGT07 (1445)	-	T1	cp4 epsps (aroA:CP4)
Cotton	EE-GH3	-	T1	mepsps
Cotton	EE-GH5	-	T7	cry1Ab
Cotton	MON88701	MON-88701-3	T3,T12	Modified dmo; bar
Cotton	OsCr11	-	T13	Modified Cry j
Flax	FP967	CDC-FL001-2	T11	als
Lentil	RH44	-	T16	als
Maize	3272	SYN-E3272-5	T17	amy797E
Maize	5307	SYN-05307-1	T7	ecry3.1Ab
Maize	59122	DAS-59122-7	T3,T7	cry34Ab1; cry35Ab1; pat
Maize	676	PH-000676-7	T3,T18	pat; dam
Maize	678	PH-000678-9	T3,T18	pat; dam
Maize	680	PH-000680-2	T3,T18	pat; dam
Maize	98140	DP-098140-6	T1,T11	gat4621; zm-hra
Maize	Bt10	-	T3,T7	cry1Ab; pat
Maize	Bt176 (176)	SYN-EV176-9	T3,T7	cry1Ab; bar
Maize	BVLA430101	-	T4	phyA2
Maize	CBH-351	ACS-ZM004-3	T3,T7	cry9C; bar
Maize	DAS40278-9	DAS40278-9	T19	aad-1
Maize	DBT418	DKB-89614-9	T3,T7	cry1Ac; pinII; bar
Maize	DLL25 (B16)	DKB-89790-5	T3	bar

Maize	GA21	MON-00021-9	T1	mepsps
Maize	GG25	-	T1	mepsps
Maize	GJ11	-	T1	mepsps
Maize	FI117	-	T1	mepsps
Maize	GAT-ZM1	-	T3	pat
Maize	LY038	REN-00038-3	T20	cordapA
Maize	MIR162	SYN-IR162-4	T7	vip3Aa20
Maize	MIR604	SYN-IR604-5	T7	mcry3A
Maize	MON801 (MON80100)	MON801	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON802	MON-80200-7	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON809	PH-MON-809-2	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON810	MON-00810-6	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON832	-	T1	cp4 epsps (aroA:CP4); goxv247
Maize	MON863	MON-00863-5	T7	cry3Bb1
Maize	MON87427	MON-87427-7	T1	cp4 epsps (aroA:CP4)
Maize	MON87460	MON-87460-4	T21	cspB
Maize	MON88017	MON-88017-3	T1,T7	cry3Bb1; cp4 epsps (aroA:CP4)
Maize	MON89034	MON-89034-3	T7	cry2Ab2; cry1A.105
Maize	MS3	ACS-ZM001-9	T3,T18	bar; barnase
Maize	MS6	ACS-ZM005-4	T3,T18	bar; barnase
Maize	NK603	MON-00603-6	T1	cp4 epsps (aroA:CP4)
Maize	T14	ACS-ZM002-1	T3	pat (syn)
Maize	T25	ACS-ZM003-2	T3	pat (syn)
Maize	TC1507	DAS-01507-1	T3,T7	cry1Fa2; pat
Maize	TC6275	DAS-06275-8	T3,T7	mocry1F; bar
Maize	VIP1034	-	T3,T7	vip3A; pat
Maize	43A47	DP-043A47-3	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	40416	DP-040416-8	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	32316	DP-032316-8	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	4114	DP-004114-3	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Melon	Melon A	-	T22	sam-k
Melon	Melon B	-	T22	sam-k
Papaya	55-1	CUH-CP551-8	T6	prsv cp
Papaya	63-1	CUH-CP631-7	T6	prsv cp
Papaya	Huanong No. 1	-	T6	prsv rep
Papaya	X17-2	UFL-X17CP-6	T6	prsv cp
Plum	C-5	ARS-PLMC5-6	T6	ppv cp
Canola**	ZSR500	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR502	-	T1	cp4 epsps (aroA:CP4); goxv247

Canola**	ZSR503	-	T1	cp4 epsps (aroA:CP4); goxv247
Rice	7Crp#242-95-7	-	T13	7crp
Rice	7Crp#10	-	T13	7crp
Rice	GM Shanyou 63	-	T7	cry1Ab; cry1Ac
Rice	Huahui-1/TT51-1	-	T7	cry1Ab; cry1Ac
Rice	LLRICE06	ACS-OS001-4	T3	bar
Rice	LLRICE601	BCS-OS003-7	T3	bar
Rice	LLRICE62	ACS-OS002-5	T3	bar
Rice	Tarom molaii + cry1Ab	-	T7	cry1Ab (truncated)
Rice	GAT-OS2	-	T3	bar
Rice	GAT-OS3	-	T3	bar
Rice	PE-7	-	T7	Cry1Ac
Rice	7Crp#10	-	T13	7crp
Rice	KPD627-8	-	T27	OASA1D
Rice	KPD722-4	-	T27	OASA1D
Rice	KA317	-	T27	OASA1D
Rice	HW5	-	T27	OASA1D
Rice	HW1	-	T27	OASA1D
Rice	B-4-1-18	-	T28	Δ OsBRI1
Rice	G-3-3-22	-	T29	OSGA2ox1
Rice	AD77	-	T6	DEF
Rice	AD51	-	T6	DEF
Rice	AD48	-	T6	DEF
Rice	AD41	-	T6	DEF
Rice	13pNasNa800725atAprt1	-	T30	HvNAS1; HvNAAT-A; APRT
Rice	13pAprt1	-	T30	APRT
Rice	gHvNAS1-gHvNAAT-1	-	T30	HvNAS1; HvNAAT-A; HvNAAT-B
Rice	gHvIDS3-1	-	T30	HvIDS3
Rice	gHvNAAT1	-	T30	HvNAAT-A; HvNAAT-B
Rice	gHvNAS1-1	-	T30	HvNAS1
Rice	NIA-OS006-4	-	T6	WRKY45
Rice	NIA-OS005-3	-	T6	WRKY45
Rice	NIA-OS004-2	-	T6	WRKY45
Rice	NIA-OS003-1	-	T6	WRKY45
Rice	NIA-OS002-9	-	T6	WRKY45
Rice	NIA-OS001-8	-	T6	WRKY45
Rice	OsCr11	-	T13	Modified Cry j
Rice	17053	-	T1	cp4 epsps (aroA:CP4)
Rice	17314	-	T1	cp4 epsps (aroA:CP4)
Rose	WKS82 / 130-4-1	IFD-52401-4	T9	5AT; bp40 (f3'5'h)
Rose	WKS92 / 130-9-1	IFD-52901-9	T9	5AT; bp40 (f3'5'h)

Soybean	260-05 (G94-1, G94-19, G168)	-	T9	gm-fad2-1 (silencing locus)
Soybean	A2704-12	ACS-GM005-3	T3	pat
Soybean	A2704-21	ACS-GM004-2	T3	pat
Soybean	A5547-127	ACS-GM006-4	T3	pat
Soybean	A5547-35	ACS-GM008-6	T3	pat
Soybean	CV127	BPS-CV127-9	T16	csr1-2
Soybean	DAS68416-4	DAS68416-4	T3	pat
Soybean	DP305423	DP-305423-1	T11,T31	gm-fad2-1 (silencing locus); gm-hra
Soybean	DP356043	DP-356043-5	T1,T31	gm-fad2-1 (silencing locus); gat4601
Soybean	FG72	MST-FG072-3	T32,T1	2mepsps; hppdPF W336
Soybean	GTS 40-3-2 (40-3-2)	MON-04032-6	T1	cp4 epsps (aroA:CP4)
Soybean	GU262	ACS-GM003-1	T3	pat
Soybean	MON87701	MON-87701-2	T7	cry1Ac
Soybean	MON87705	MON-87705-6	T1,T31	fatb1-A (sense & antisense); fad2-1A (sense & antisense); cp4 epsps (aroA:CP4)
Soybean	MON87708	MON-87708-9	T1,T12	dmo; cp4 epsps (aroA:CP4)
Soybean	MON87769	MON-87769-7	T1,T31	Pj.D6D; Nc.Fad3; cp4 epsps (aroA:CP4)
Soybean	MON89788	MON-89788-1	T1	cp4 epsps (aroA:CP4)
Soybean	W62	ACS-GM002-9	T3	bar
Soybean	W98	ACS-GM001-8	T3	bar
Soybean	MON87754	MON-87754-1	T33	dgal2A
Soybean	DAS21606	DAS-21606	T34,T3	Modified aad-12; pat
Soybean	DAS44406	DAS-44406-6	T1,T3,T34	Modified aad-12; 2mepsps; pat
Soybean	SYHT04R	SYN-0004R-8	T35	Modified avhppd
Soybean	9582.814.19.1	-	T3,T7	cry1Ac, cry1F, PAT
Squash	CZW3	SEM-ØCZW3-2	T6	cmv cp, zymv cp, wmv cp
Squash	ZW20	SEM-0ZW20-7	T6	zymv cp, wmv cp
Sugar Beet	GTSB77 (T9100152)	SY-GTSB77-8	T1	cp4 epsps (aroA:CP4); goxv247
Sugar Beet	H7-1	KM-000H71-4	T1	cp4 epsps (aroA:CP4)
Sugar Beet	T120-7	ACS-BV001-3	T3	pat
Sugar Beet	T227-1	-	T1	cp4 epsps (aroA:CP4)
Sugarcane	NXI-1T	-	T21	EcbetA
Sunflower	X81359	-	T16	als
Pepper	PK-SP01	-	T6	cmv cp
Tobacco	C/F/93/08-02	-	T5	bxn
Tobacco	Vector 21-41	-	T36	NtQPT1 (antisense)

Sunflower	X81359	-	T16	als
Wheat	MON71800	MON-71800- 3	T1	cp4 epsps (aroA:CP4)

* Argentine (*Brassica napus*), ** Polish (*B. rapa*), # Eggplant

Although most typically, compounds of the invention are used to control undesired vegetation, contact of desired vegetation in the treated locus with compounds of the invention may result in super-additive or synergistic effects with genetic traits in the desired vegetation, including traits incorporated through genetic modification. For example, 5 resistance to phytophagous insect pests or plant diseases, tolerance to biotic/abiotic stresses or storage stability may be greater than expected from the genetic traits in the desired vegetation.

Compounds of this invention can also be mixed with one or more other biologically 10 active compounds or agents including herbicides, herbicide safeners, fungicides, insecticides, nematocides, bactericides, acaricides, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or 15 entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Mixtures of the compounds of the invention with other herbicides can broaden the spectrum of activity against additional weed species, and suppress the proliferation of any resistant biotypes. Thus the present invention 20 also pertains to a composition comprising a compound of Formula 1 (in a herbicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount) and can further comprise at least one of a surfactant, a solid 25 diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of the present invention, one or more other biologically active compounds or agents can be formulated together with a compound of Formula 1, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1, and the formulations combined together before application (e.g., in 30 a spray tank) or, alternatively, applied in succession.

A mixture of one or more of the following herbicides with a compound of this 35 invention may be particularly useful for weed control: acetochlor, acifluorfen and its sodium salt, aclonifen, acrolein (2-propenal), alachlor, alloxydim, ametryn, amicarbazone, amidosulfuron, aminocyclopyrachlor and its esters (e.g., methyl, ethyl) and salts (e.g., sodium, potassium), aminopyralid, amitrole, ammonium sulfamate, anilofos, asulam, atrazine, azimsulfuron, beflubutamid, benazolin, benazolin-ethyl, bencarbazone, benfluralin, 40 benfuresate, bensulfuron-methyl, bensulide, bentazone, benzobicyclon, benzofenap, bicyclopyrone, bifenoxy, bilanafos, bispyribac and its sodium salt, bromacil, bromobutide, bromofenoxim, bromoxynil, bromoxynil octanoate, butachlor, butafenacil, butamifos,

butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone-ethyl, catechin, chlomethoxyfen, chloramben, chlorbromuron, chlorflurenol-methyl, chloridazon, chlorimuron-ethyl, chlorotoluron, chlorpropham, chlorsulfuron, chlorthal-dimethyl, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, clacyfos, clefoxydim, clethodim, 5 clodinafop-propargyl, clomazone, clomeprop, clopyralid, clopyralid-olamine, cloransulam-methyl, cumyluron, cyanazine, cycloate, cyclopyrimorate, cyclosulfamuron, cycloxydim, cyhalofop-butyl, 2,4-D and its butotyl, butyl, isooctyl and isopropyl esters and its dimethylammonium, diolamine and trolamine salts, daimuron, dalapon, dalapon-sodium, dazomet, 2,4-DB and its dimethylammonium, potassium and sodium salts, desmedipham, 10 desmetryn, dicamba and its diglycolammonium, dimethylammonium, potassium and sodium salts, dichlobenil, dichlorprop, diclofop-methyl, diclosulam, difenzoquat metilsulfate, diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimethipin, dimethylarsinic acid and its sodium salt, dinitramine, dinoterb, diphenamid, diquat dibromide, dithiopyr, diuron, DNOC, endothal, 15 EPTC, esprocarb, ethalfluralin, ethametsulfuron-methyl, ethiozin, ethofumesate, ethoxyfen, ethoxysulfuron, etobenzanid, fenoxaprop-ethyl, fenoxaprop-P-ethyl, fenoxasulfone, fenquinotrione, fentrazamide, fenuron, fenuron-TCA, flamprop-methyl, flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron, florasulam, fluazifop-butyl, fluazifop-P-butyl, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, 20 flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac-pentyl, flumioxazin, fluometuron, fluoroglycofen-ethyl, flupoxam, fluprysulfuron-methyl and its sodium salt, flurenol, flurenol-butyl, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiacet-methyl, fomesafen, foramsulfuron, fosamine-ammonium, glufosinate, glufosinate-ammonium, glufosinate-P, glyphosate and its salts such as ammonium, isopropylammonium, potassium, 25 sodium (including sesquisodium) and trimesium (alternatively named sulfosate), halauxifen, halauxifen-methyl, halosulfuron-methyl, haloxyfop-etyl, haloxyfop-methyl, hexazinone, hydantocidin, imazamethabenz-methyl, imazamox, imazapic, imazapyr, imazaquin, imazaquin-ammonium, imazethapyr, imazethapyr-ammonium, imazosulfuron, indanofan, indaziflam, iofensulfuron, iodosulfuron-methyl, ioxynil, ioxynil octanoate, ioxynil-sodium, 30 ipfencarbazone, isoproturon, isouron, isoxaben, isoxaflutole, isoxachlortole, lactofen, lenacil, linuron, maleic hydrazide, MCPA and its salts (e.g., MCPA-dimethylammonium, MCPA-potassium and MCPA-sodium, esters (e.g., MCPA-2-ethylhexyl, MCPA-butotyl) and thioesters (e.g., MCPA-thioethyl), MCPB and its salts (e.g., MCPB-sodium) and esters (e.g., MCPB-ethyl), mecoprop, mecoprop-P, mefenacet, mefluidide, mesosulfuron-methyl, 35 mesotrione, metam-sodium, metamifop, metamitron, metazachlor, metazosulfuron, methabenzthiazuron, methylarsonic acid and its calcium, monoammonium, monosodium and disodium salts, methyldymron, metobenzuron, metobromuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin, metsulfuron-methyl, molinate, monolinuron,

naproanilide, napropamide, napropamide-M, naptalam, neburon, nicosulfuron, norflurazon, orbencarb, orthosulfamuron, oryzalin, oxadiargyl, oxadiaxon, oxasulfuron, oxaziclofone, oxyfluorfen, paraquat dichloride, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentanochlor, pentozazone, perfluidone, pethoxamid, pethoxyamid, phenmedipham, 5 picloram, picloram-potassium, picolinafen, pinoxaden, piperophos, pretilachlor, primisulfuron-methyl, prodiamine, profoxydim, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, prophan, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfocarb, prosulfuron, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazogyl, pyrazolynate, pyrazoxyfen, pyrazosulfuron-ethyl, pyribenzoxim, pyributicarb, 10 pyridate, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyrithiobac-sodium, pyroxasulfone, pyroxasulam, quinclorac, quinmerac, quinoclamine, quizalofop-ethyl, quizalofop-P-ethyl, quizalofop-P-tefuryl, rimsulfuron, saflufenacil, sethoxydim, siduron, simazine, simetryn, sulcotrione, sulfentrazone, sulfometuron-methyl, sulfosulfuron, 2,3,6-TBA, TCA, TCA-sodium, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, 15 terbacil, terbumeton, terbutylazine, terbutryn, thenylchlor, thiazopyr, thiencarbazone, thifensulfuron-methyl, thiobencarb, tiafenacil, tiocarbazil, tolpyralate, topramezone, tralkoxydim, tri-allate, triafamone, triasulfuron, triaziflam, tribenuron-methyl, triclopyr, triclopyr-butotyl, triclopyr-triethylammonium, tridiphane, trietazine, trifloxsulfuron, trifludimoxazin, trifluralin, triflusulfuron-methyl, tritosulfuron, vernolate, 3-(2-chloro-3,6-difluorophenyl)-4-hydroxy-1-methyl-1,5-naphthyridin-2(1H)-one, 5-chloro-3-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-1-(4-methoxyphenyl)-2(1H)-quinoxalinone, 2-chloro-N-(1-methyl-1H-tetrazol-5-yl)-6-(trifluoromethyl)-3-pyridinecarboxamide, 7-(3,5-dichloro-4-pyridinyl)-5-(2,2-difluoroethyl)-8-hydroxypyrido[2,3-*b*]pyrazin-6(5H)-one, 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-dimethyl-3(2H)-pyridazinone, 5-[(2,6-difluorophenyl)methoxy]methyl]-4,5-dihydro-5-methyl-3-(3-methyl-2-thienyl)isoxazole (previously methioxolin), 4-(4-fluorophenyl)-6-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione, methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-5-fluoro-2-pyridinecarboxylate, 2-methyl-3-(methylsulfonyl)-*N*-(1-methyl-1H-tetrazol-5-yl)-4-(trifluoromethyl)benzamide and 2-methyl-30 *N*-(4-methyl-1,2,5-oxadiazo-3-yl)-3-(methylsulfinyl)-4-(trifluoromethyl)benzamide. Other herbicides also include bioherbicides such as *Alternaria destruens* Simmons, *Colletotrichum gloeosporioides* (Penz.) Penz. & Sacc., *Drechslera monoceras* (MTB-951), *Myrothecium verrucaria* (Albertini & Schweinitz) Ditmar: Fries, *Phytophthora palmivora* (Butl.) Butl. and *Puccinia thlaspeos* Schub..

35 Compounds of this invention can also be used in combination with plant growth regulators such as aviglycine, *N*-(phenylmethyl)-1*H*-purin-6-amine, epocholeone, gibberellic acid, gibberellin A₄ and A₇, harpin protein, mepiquat chloride, prohexadione calcium,

prohydrojasmon, sodium nitrophenolate and trinexapac-methyl, and plant growth modifying organisms such as *Bacillus cereus* strain BP01.

General references for agricultural protectants (i.e. herbicides, herbicide safeners, insecticides, fungicides, nematocides, acaricides and biological agents) include *The Pesticide Manual, 13th Edition*, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and *The BioPesticide Manual, 2nd Edition*, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001.

For embodiments where one or more of these various mixing partners are used, the mixing partners are typically used in the amounts similar to amounts customary when the mixture partners are used alone. More particularly in mixtures, active ingredients are often applied at an application rate between one-half and the full application rate specified on product labels for use of active ingredient alone. These amounts are listed in references such as *The Pesticide Manual* and *The BioPesticide Manual*. The weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:300 and about 300:1 (for example ratios between about 1:30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity. It will be evident that including these additional components may expand the spectrum of weeds controlled beyond the spectrum controlled by the compound of Formula 1 alone.

In certain instances, combinations of a compound of this invention with other biologically active (particularly herbicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect on weeds and/or a less-than-additive effect (i.e. safening) on crops or other desirable plants. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. Ability to use greater amounts of active ingredients to provide more effective weed control without excessive crop injury is also desirable. When synergism of herbicidal active ingredients occurs on weeds at application rates giving agronomically satisfactory levels of weed control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load. When safening of herbicidal active ingredients occurs on crops, such combinations can be advantageous for increasing crop protection by reducing weed competition.

Of note is a combination of a compound of the invention with at least one other herbicidal active ingredient. Of particular note is such a combination where the other herbicidal active ingredient has different site of action from the compound of the invention. In certain instances, a combination with at least one other herbicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further

comprise (in a herbicidally effective amount) at least one additional herbicidal active ingredient having a similar spectrum of control but a different site of action.

Compounds of this invention can also be used in combination with herbicide safeners such as allidochlor, benoxacor, cloquintocet-mexyl, cumyluron, cyometrinil, cyprosulfamide, daimuron, dichlormid, dicyclonon, dietholate, dimepiperate, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, mephenate, methoxyphenone naphthalic anhydride (1,8-naphthalic anhydride), oxabetrinil, *N*-(aminocarbonyl)-2-methylbenzenesulfonamide, *N*-(aminocarbonyl)-2-fluorobenzenesulfonamide, 1-bromo-4-[(chloromethyl)sulfonyl]benzene (BCS), 4-(dichloroacetyl)-1-oxa-4-azospiro[4.5]decane (MON 4660), 2-(dichloromethyl)-2-methyl-1,3-dioxolane (MG 191), ethyl 1,6-dihydro-1-(2-methoxyphenyl)-6-oxo-2-phenyl-5-pyrimidinecarboxylate, 2-hydroxy-*N,N*-dimethyl-6-(trifluoromethyl)pyridine-3-carboxamide, and 3-oxo-1-cyclohexen-1-yl 1-(3,4-dimethylphenyl)-1,6-dihydro-6-oxo-2-phenyl-5-pyrimidinecarboxylate, 2,2-dichloro-1-(2,2,5-trimethyl-3-oxazolidinyl)-ethanone and 2-methoxy-*N*-[[4-[(methylamino)carbonyl]amino]phenyl]sulfonyl]-benzamide to increase safety to certain crops. Antidotally effective amounts of the herbicide safeners can be applied at the same time as the compounds of this invention, or applied as seed treatments. Therefore an aspect of the present invention relates to a herbicidal mixture comprising a compound of this invention and an antidotally effective amount of a herbicide safener. Seed treatment is particularly useful for selective weed control, because it physically restricts antidoting to the crop plants. Therefore a particularly useful embodiment of the present invention is a method for selectively controlling the growth of undesired vegetation in a crop comprising contacting the locus of the crop with a herbicidally effective amount of a compound of this invention wherein seed from which the crop is grown is treated with an antidotally effective amount of safener. Antidotally effective amounts of safeners can be easily determined by one skilled in the art through simple experimentation.

Compounds of the invention can also be mixed with: (1) polynucleotides including but not limited to DNA, RNA, and/or chemically modified nucleotides influencing the amount of a particular target through down regulation, interference, suppression or silencing of the genetically derived transcript that render a herbicidal effect; or (2) polynucleotides including but not limited to DNA, RNA, and/or chemically modified nucleotides influencing the amount of a particular target through down regulation, interference, suppression or silencing of the genetically derived transcript that render a safening effect.

Of note is a composition comprising a compound of the invention (in a herbicidally effective amount), at least one additional active ingredient selected from the group consisting of other herbicides and herbicide safeners (in an effective amount), and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.

Preferred for better control of undesired vegetation (e.g., lower use rate such as from synergism, broader spectrum of weeds controlled, or enhanced crop safety) or for preventing the development of resistant weeds are mixtures of a compound of this invention with another herbicide. Table A1 lists particular combinations of Component (a) (i.e. a specific compound of the present invention) with another herbicide as Component (b) illustrative of the mixtures, compositions and methods of the present invention. Compound 17 in the Component (a) column is identified in Index Table A. The second column of Table A1 lists the specific Component (b) compound (e.g., "2,4-D" in the first line). The third, fourth and fifth columns of Table A1 lists ranges of weight ratios for rates at which the Component (a) compound is typically applied to a field grown crop relative to Component (b) (i.e. (a):(b)). Thus, for example, the first line of Table A1 specifically discloses the combination of Component (a) (i.e. Compound 17 in Index Table A) with 2,4 D is typically applied in a weight ratio between 1:192 – 6:1. The remaining lines of Table A1 are to be construed similarly.

15

TABLE A1

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	2,4-D	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Acetochlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Acifluorfen	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Aclonifen	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
1	Alachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Ametryn	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Amicarbazone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Amidosulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
1	Aminocyclopyrachlor	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
1	Aminopyralid	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Amitrole	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Anilofos	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Asulam	1:960 – 2:1	1:320 – 1:3	1:120 – 1:14
1	Atrazine	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Azimsulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
1	Beflubutamid	1:342 – 4:1	1:114 – 2:1	1:42 – 1:5
1	Benfuresate	1:617 – 2:1	1:205 – 1:2	1:77 – 1:9
1	Bensulfuron-methyl	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Bentazone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Benzobicyclon	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Benzofenap	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
1	Bicyclyrone	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Bifenox	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
1	Bispyribac-sodium	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Bromacil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Bromobutide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Bromoxynil	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Butachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Butafenacil	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Butylate	1:1542 – 1:2	1:514 – 1:5	1:192 – 1:22
1	Carfenstrole	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Carfentrazone-ethyl	1:128 – 9:1	1:42 – 3:1	1:16 – 1:2
1	Chlorimuron-ethyl	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Chlorotoluron	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Chlorsulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
1	Cincosulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Cinidon-ethyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Cinmethylin	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
1	Clacyfos	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
1	Clethodim	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
1	Clodinafop-propargyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Clomazone	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Clomeprop	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3
1	Clopyralid	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Cloransulam-methyl	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
1	Cumyluron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Cyanazine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Cyclopyrimorate	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Cyclosulfamuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Cycloxydim	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Cyhalofop	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Daimuron	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Desmedipham	1:322 – 4:1	1:107 – 2:1	1:40 – 1:5
1	Dicamba	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Dichlobenil	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Dichlorprop	1:925 – 2:1	1:308 – 1:3	1:115 – 1:13
1	Diclofop-methyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Diclosulam	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Difenoquat	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Diflufenican	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
1	Diflufenzopyr	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
1	Dimethachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Dimethametryn	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Dimethenamid-P	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Dithiopyr	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Diuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	EPTC	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Esprocarb	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20
1	Ethalfluralin	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Ethametsulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Ethoxyfen	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Ethoxysulfuron	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Etobenzanid	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
1	Fenoxaprop-ethyl	1:120 – 10:1	1:40 – 4:1	1:15 – 1:2
1	Fenoxyasulfone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
1	Fenquinotrione	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Fentrazamide	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Flazasulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Florasulam	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
1	Fluazifop-butyl	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Flucarbazone	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Flucetosulfuron	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Flufenacet	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
1	Flumetsulam	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
1	Flumiclorac-pentyl	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Flumioxazin	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Fluometuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Flupyrtsulfuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
1	Fluridone	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Fluroxypyrr	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Flurtamone	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
1	Fluthiacet-methyl	1:48 – 42:1	1:16 – 14:1	1:3 – 3:1
1	Fomesafen	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Foramsulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
1	Glufosinate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Glyphosate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Halosulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Halauxifen	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Halauxifen-methyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Haloxyfop-methyl	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
1	Hexazinone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Hydantocidin	1:1100 – 16:1	1:385 – 8:1	1:144 – 4:1
1	Imazamox	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
1	Imazapic	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Imazapyr	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
1	Imazaquin	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
1	Imazethabenz-methyl	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3
1	Imazethapyr	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
1	Imazosulfuron	1:27 – 42:1	1:9 – 14:1	1:3 – 3:1
1	Indanofan	1:342 – 4:1	1:114 – 2:1	1:42 – 1:5
1	Indaziflam	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Iodosulfuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
1	Ioxynil	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Ipfencarbazone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
1	Isoproturon	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Isoxaben	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Isoxaflutole	1:60 – 20:1	1:20 – 7:1	1:7 – 2:1
1	Lactofen	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Lenacil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Linuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	MCPA	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	MCPB	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Mecoprop	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Mefenacet	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Mefluidide	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Mesosulfuron-methyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Mesotrione	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Metamifop	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Metazachlor	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Metazosulfuron	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Methabenzthiazuron	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Metolachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Metosulam	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Metribuzin	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Metsulfuron-methyl	1:2 – 560:1	1:1 – 187:1	3:1 – 35:1
1	Molinate	1:1028 – 2:1	1:342 – 1:3	1:128 – 1:15
1	Napropamide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Napropamide-M	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Naptalam	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Nicosulfuron	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
1	Norflurazon	1:1152 – 1:1	1:384 – 1:3	1:144 – 1:16
1	Orbencarb	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20
1	Orthosulfamuron	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Oryzalin	1:514 – 3:1	1:171 – 1:2	1:64 – 1:8
1	Oxadiargyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Oxadiazon	1:548 – 3:1	1:182 – 1:2	1:68 – 1:8
1	Oxasulfuron	1:27 – 42:1	1:9 – 14:1	1:3 – 3:1
1	Oxaziclomefone	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Oxyfluorfen	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Paraquat	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Pendimethalin	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Penoxsulam	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Penthoxamid	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Pentoxazone	1:102 – 12:1	1:34 – 4:1	1:12 – 1:2
1	Phenmedipham	1:102 – 12:1	1:34 – 4:1	1:12 – 1:2
1	Picloram	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Picolinafen	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
1	Pinoxaden	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Pretilachlor	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Primsulfuron-methyl	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Prodiamine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Profoxydim	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Prometryn	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Propachlor	1:1152 – 1:1	1:384 – 1:3	1:144 – 1:16
1	Propanil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Propaquizafop	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
1	Propoxycarbazone	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Propyrisulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Propyzamide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Prosulfocarb	1:1200 – 1:2	1:400 – 1:4	1:150 – 1:17
1	Prosulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
1	Pyraclonil	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Pyraflufen-ethyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Pyrasulfotole	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
1	Pyrazolynate	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
1	Pyrazosulfuron-ethyl	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Pyrazoxyfen	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Pyribenzoxim	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Pyributicarb	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Pyridate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Pyriftalid	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
1	Pyriminobac-methyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
1	Pyrimisulfan	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Pyrithiobac	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
1	Pyroxasulfone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
1	Pyroxsulam	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Quinclorac	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Quizalofop-ethyl	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Rimsulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
1	Saflufenacil	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Sethoxydim	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
1	Simazine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Sulcotrione	1:120 – 10:1	1:40 – 4:1	1:15 – 1:2
1	Sulfentrazone	1:147 – 8:1	1:49 – 3:1	1:18 – 1:3
1	Sulfometuron-methyl	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1


<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
1	Sulfosulfuron	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
1	Tebuthiuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Tefuryltrione	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
1	Tembotrione	1:31 – 37:1	1:10 – 13:1	1:3 – 3:1
1	Tepraloxymid	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Terbacil	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Terbutylazine	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
1	Terbutryn	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Thenylchlor	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
1	Thiazopyr	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
1	Thiencarbazone	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
1	Thifensulfuron-methyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Tiafenacil	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Thiobencarb	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Tolpyralate	1:31 – 37:1	1:10 – 13:1	1:3 – 3:1
1	Topramzone	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
1	Tralkoxydim	1:68 – 17:1	1:22 – 6:1	1:8 – 2:1
1	Triafamone	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
1	Triallate	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
1	Triasulfuron	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
1	Triaziflam	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3
1	Tribenuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
1	Triclopyr	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
1	Trifloxysulfuron	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
1	Trifludimoxazin	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
1	Trifluralin	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
1	Triflusulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
1	Tritosulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1

Table A2 is constructed the same as Table A1 above except that entries below the “Component (a)” column heading are replaced with the respective Component (a) Column Entry shown below. Compound 2 in the Component (a) column is identified in Index Table A. Thus, for example, in Table A2 the entries below the “Component (a) Column Entries” heading all recite “Compound 2” (i.e. Compound 2 as identified in Index Table A), and the first line below the column headings in Table A2 specifically discloses a mixture of Compound 2 with 2,4-D. Tables A3 through A35 are constructed similarly.

<u>Table Number</u>	<u>Component (a) Column Entries</u>	<u>Table Number</u>	<u>Component (a) Column Entries</u>
A2	Compound 2	A19	Compound 19
A3	Compound 3	A20	Compound 20
A4	Compound 4	A21	Compound 21
A5	Compound 5	A22	Compound 22
A6	Compound 6	A23	Compound 23
A7	Compound 7	A24	Compound 24
A8	Compound 8	A25	Compound 25
A9	Compound 9	A26	Compound 26
A10	Compound 10	A27	Compound 27
A11	Compound 11	A28	Compound 28
A12	Compound 12	A29	Compound 29
A13	Compound 13	A30	Compound 30
A14	Compound 14	A31	Compound 31
A15	Compound 15	A32	Compound 32
A16	Compound 16	A33	Compound 33
A17	Compound 17	A34	Compound 34
A18	Compound 18	A35	Compound 35

Preferred for better control of undesired vegetation (e.g., lower use rate such as from synergism, broader spectrum of weeds controlled, or enhanced crop safety) or for preventing the development of resistant weeds are mixtures of a compound of this invention with a herbicide selected from the group consisting of chlorimuron-ethyl, nicosulfuron, mesotrione, 5 thifensulfuron-methyl, flupyrifuron-methyl, tribenuron, pyroxasulfone, pinoxaden, tembotrione, pyroxasulfone, metolachlor and S-metolachlor.

The following Tests demonstrate the control efficacy of the compounds of this invention against specific weeds. The weed control afforded by the compounds is not limited, however, to these species. See Index Table A for compound descriptions. The 10 following abbreviations are used in the Index Tables which follow: Ph is phenyl. The abbreviation "Cmpd. No." stands for "Compound Number". The abbreviation "Ex." stands for "Example" and is followed by a number indicating in which example the compound is prepared. Mass spectra are reported with an estimated precision within ± 0.5 Da as the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of 15 H⁺ (molecular weight of 1) to the molecule observed by using atmospheric pressure chemical ionization (AP⁺). As depicted below for variable A, the bond projecting to the left is connected to the Q¹ moiety, and the bond projecting to the right is connected to the remainder of Formula 1.

INDEX TABLE A

Cmpd. No.	Q ¹	Q ²	A	m.p. (°C)	M-1	M+1
1	Ph(3-Cl)	Ph(2,3-di-F)	-CH ₂ -	132-134		
2	Ph(3-Cl)	Ph(2-F)	-CH ₂ -	122-125		
3	Ph	Ph(2-F)	-CH ₂ -	132-135		
4	Ph	Ph(2,3-di-F)	-CH ₂ -	182-185		
5	Ph(2-CF ₃)	Ph(2-CF ₃)	-CH ₂ -		429	431
6	Ph(4-CF ₃)	Ph(2-CF ₃)	-CH ₂ -	136-139		
7	Ph(4-CF ₃)	Ph(2,3-di-F)	-CH ₂ -	198-201		
8	Ph(2,3-di-F)	Ph(2,3-di-F)	-CH ₂ -	149-153		
9	Ph(2-CF ₃)	Ph(2,3-di-F)	-CH ₂ -	173-177		
10	Ph(2,3-di-F)	Ph(2-CF ₃)	-CH ₂ -	131-135		
11	Ph(3-CF ₃)	Ph(2,3-di-F)	-CH ₂ -	179-182		
12	Ph(3,4-di-F)	Ph(2,3-di-F)	-CH ₂ -	162-168		
13 (Ex. 1)	Ph(4-F)	Ph(2,3-di-F)	-CH ₂ -	173-176		
14	Ph(4-F)	Ph(2-F)	-CH ₂ -	135-138		
15	Ph(4-F)	Ph(2-F)	-NHC(=O)(CH ₂) ₂ -		386	388
16	Ph(4-F)	Ph(2,3-di-F)	-C≡C-	185-188		
17	Ph(4-F)	Ph(2,3,4-tri-F)	-C≡C-	186-189		
18	Ph(3-CF ₃)	Ph(2,3-di-F)	-NHC(=O)-		426	428
19	Ph(4-F)	Ph(2-F)	-C≡C-	184-187		
20	Ph	Ph(2-F)	-(CH ₂) ₂ -	141-144		
21	Ph(3-CH ₃)	Ph(2-F)	-C≡C-	123-127		
22	Ph(3-CH ₃)	Ph(2,3-di-F)	-C≡C-	155-157		
23	Ph(3-CH ₃)	Ph(2,3,4-tri-F)	-C≡C-	172-176		
24	Ph(3-F)	Ph(2-F)	-HC=CH- *	168-172		
25 (Ex. 4)	Ph(3-Cl)	Ph(2,3-di-F)	-C≡C-	154-156		
26	Ph(3-Cl)	Ph(2,3,4-tri-F)	-C≡C-	178-182		
27	Ph(4-F)	Ph(2-F)	-HC=CH- *	160-163		
28	Ph(2-F)	Ph(2,3-di-F)	-HC=CH- *	204-206		
29	Ph(3-Cl)	Ph(2-F)	-C≡C-	120-124		

Cmpd. No.	Q ¹	Q ²	A	m.p. (°C)	M-1	M+1
30	Ph(3-F)	Ph(2,3-di-F)	-HC=CH- *	181-185		
31	Ph(4-F)	Ph(2,3-di-F)	-HC=CH- *	194-197		
32	Ph	Ph(2-F)	-HC=CH- *	160-164		
33 (Ex. 2)	Ph	Ph(2,3-di-F)	-HC=CH- *	200-204		
34	Ph(2-F)	Ph(2-F)	-HC=CH- *	161-164		
35 (Ex. 3)	Ph	Ph(2,3-di-F)	-(CH ₂) ₂ -	142-145		

* Prepared as the *E* isomer

BIOLOGICAL EXAMPLES OF THE INVENTION

TEST A

Seeds of plant species selected from barnyardgrass (*Echinochloa crus-galli*), crabgrass (large crabgrass, *Digitaria sanguinalis*), kochia (*Kochia scoparia*), ragweed (common ragweed, *Ambrosia elatior*), morningglory (*Ipomoea* spp.), velvetleaf (*Abutilon theophrasti*), ryegrass, It. (Italian ryegrass, *Lolium multiflorum*), foxtail, giant (giant foxtail, *Setaria faberii*), wheat (*Triticum aestivum*), corn (*Zea mays*), and pigweed (*Amaranthus retroflexus*), were planted into a blend of loam soil and sand and treated preemergence with a directed soil spray using test chemicals formulated in a non-phytotoxic solvent mixture which included a surfactant.

At the same time, plants selected from these crop and weed species and also blackgrass (*Alopecurus myosuroides*), and galium (catchweed bedstraw, *Galium aparine*), were planted in pots containing the same blend of loam soil and sand and treated with postemergence applications of test chemicals formulated in the same manner. Plants ranged in height from 2 to 10 cm and were in the one- to two-leaf stage for the postemergence treatment. Treated plants and untreated controls were maintained in a greenhouse for approximately 10 d, after which time all treated plants were compared to untreated controls and visually evaluated for injury. Plant response ratings, summarized in Table A, are based on a 0 to 100 scale where 0 is no effect and 100 is complete control. A dash (-) response means no test result.

Table	A	Compounds					
		1	2	3	4	13	14
1000 g ai/ha							
Postemergence							
Barnyardgrass	80	30	0	0	80	0	
25 Corn	0	0	0	0	0	0	
Crabgrass	80	80	0	20	80	20	
Foxtail, Giant	80	60	0	0	60	0	
Morningglory	0	0	0	0	0	0	
Pigweed	0	0	0	0	0	0	
30 Velvetleaf	10	0	0	0	0	0	

91

Table A Compounds

Table A Compounds
1000 g ai/ha 1 2 3 4 13 14

Preemergence							
20	Barnyardgrass	70	30	0	0	80	20
	Corn	0	0	0	0	0	0
	Crabgrass	90	90	0	60	80	80
	Foxtail, Giant	90	80	0	0	60	30
	Morningglory	0	0	0	0	0	0
25	Pigweed	0	0	0	0	0	0
	Velvetleaf	0	0	0	0	0	0
	Wheat	0	0	0	0	0	0

Table A		Compounds													
500 g ai/ha		5	6	7	8	9	10	11	12	15	16	17	18	19	20
Preemergence															
Barnyardgrass		0	0	40	0	50	0	0	60	0	90	50	30	50	0
Foxtail, Giant		0	0	30	50	50	0	0	60	0	90	90	60	20	0
Kochia		0	0	0	0	50	0	0	0	0	0	0	0	0	0
Pigweed		0	0	0	0	0	0	0	0	0	0	20	0	0	0
Ragweed		0	0	0	0	30	0	0	0	0	0	0	-	0	0
Ryegrass, It.		0	0	0	0	0	0	0	0	0	0	0	20	0	0

		Compounds														
500 g ai/ha		21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
	Preemergence															
	Barnyardgrass	80	80	80	70	90	70	50	90	70	90	70	60	90	80	30
5	Foxtail, Giant	0	70	80	90	90	70	60	90	60	90	70	80	90	80	60
	Kochia	0	20	0	20	60	0	40	0	0	80	20	0	20	0	50
	Pigweed	0	0	0	0	50	40	0	0	0	0	0	0	0	100	0
	Ragweed	0	0	0	30	0	0	30	0	0	0	0	0	0	0	0
	Ryegrass, It.	20	0	0	0	0	0	20	0	0	0	0	0	0	0	0
10	Table A															
125 g ai/ha		5	6	7	8	9	10	11	12	15	16	17	18	19	20	
	Preemergence															
	Barnyardgrass	0	0	0	0	0	0	0	0	0	20	20	20	0	0	0
	Foxtail, Giant	0	0	0	0	0	0	0	0	0	60	30	50	0	0	0
15	Kochia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Pigweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ragweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ryegrass, It.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	Table A															
125 g ai/ha		21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
	Preemergence															
	Barnyardgrass	20	60	60	30	60	0	0	50	30	50	0	20	50	20	0
	Foxtail, Giant	0	50	40	60	40	0	0	50	0	60	20	0	50	20	0
	Kochia	0	0	0	0	0	0	0	0	0	70	0	0	0	0	0
25	Pigweed	0	0	0	0	0	0	0	0	0	0	0	0	0	80	0
	Ragweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ryegrass, It.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TEST B

Plant species in the flooded paddy test selected from rice (*Oryza sativa*), sedge, umbrella (small-flower umbrella sedge, *Cyperus difformis*), ducksalad (*Heteranthera limosa*), and barnyardgrass (*Echinochloa crus-galli*) were grown to the 2-leaf stage for testing. At time of treatment, test pots were flooded to 3 cm above the soil surface, treated by application of test compounds directly to the paddy water, and then maintained at that water depth for the duration of the test. Treated plants and controls were maintained in a greenhouse for 13 to 15 d, after which time all species were compared to controls and visually evaluated. Plant response ratings, summarized in Table B, are based on a scale of 0


to 100 where 0 is no effect and 100 is complete control. A dash (-) response means no test result.

Table B		Compounds		Table B		Compound								
1000 g ai/ha		1	2	250 g ai/ha		13								
Flood				Flood										
Barnyardgrass		0	0	Barnyardgrass		0								
Ducksalad		50	0	Ducksalad		0								
Rice		0	0	Rice		0								
Sedge, Umbrella		0	0	Sedge, Umbrella		0								
Table B		Compounds												
5	500 g ai/ha	5	6	7	8	9	10	11	12	15				
Flood														
Barnyardgrass		0	0	25	0	0	0	0	0	0				
Ducksalad		0	0	75	0	40	0	0	0	70				
Rice		0	0	0	0	0	0	0	0	0				
Sedge, Umbrella		0	0	0	0	0	0	0	0	0				
10	Table B	Compounds												
	250 g ai/ha	16	17	18	19	20	21	22	23	24	25	26	27	28
Flood														
Barnyardgrass		0	0	30	0	0	0	0	0	70	0	0	0	90
Ducksalad		70	70	40	0	50	40	70	0	90	85	75	80	90
15	Rice		0	0	15	0	0	0	0	0	20	0	0	10
	Sedge, Umbrella		0	0	0	0	0	0	0	0	0	0	0	50
Table B		Compounds												
20	250 g ai/ha	29	30	31	32	33	34	35						
Flood														
Barnyardgrass		0	70	40	0	40	0	0						
Ducksalad		75	95	80	70	95	80	70						
Rice		0	15	15	0	0	15	0						
	Sedge, Umbrella		0	0	50	0	0	60						

CLAIMS

What is claimed is:

1. A compound selected from Formula 1, *N* oxides and salts thereof,



5 wherein

A is a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3 atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, wherein up to 2 carbon members are independently selected from C(=O) and C(=S) and the sulfur atom member is selected from S(=O)_u(=NR⁸)_v; the said chain optionally substituted with up to 5 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms;

10 Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷; or a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

15 Q² is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected

20

25

30

from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members;

Y¹ and Y² are each independently O, S or NR¹²;

J is -CR²R³-; or -CR²R³-CR^{2a}R^{3a}- wherein the -CR²R³- moiety is directly connected to N;

R¹ is H, hydroxy, amino, cyano, formyl, C₃-C₈ alkylcarbonylalkyl, -C(C₁-C₄ alkyl)=N-O(C₁-C₄ alkyl), -C(O)NH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₂-C₈ alkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ haloalkenylalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₅-C₁₀ cycloalkylcarbonylalkyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkoxycarbonyl, C₄-C₁₀ cycloalkoxycarbonyl, C₂-C₈ alkylaminoalkyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₄-C₁₀ cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₃-C₈ cycloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl, C₃-C₁₀ trialkylsilyl; or arylcarbonyl, arylalkenylalkyl, arylcarbonylalkyl or -CPh=N-O(C₁-C₄ alkyl), each optionally substituted on ring members with up to 5 substituents independently selected from R¹³; or G¹;

R² and R³ are each independently H, halogen, hydroxy, C₁-C₄ alkyl, C₁-C₄ haloalkyl or C₁-C₄ alkoxy; or

R² and R³ are taken together with the carbon atom to which they are bonded to form a C₃-C₇ cycloalkyl ring;

R^{2a} and R^{3a} are each independently H, halogen or C₁-C₄ alkyl; or

R^{2a} and R^{3a} are taken together with the carbon atom to which they are bonded to form a C₃-C₇ cycloalkyl ring;

each R⁴ is independently H, halogen, hydroxy, C₁-C₄ alkoxy or C₁-C₄ alkyl;

each R⁵ is independently H, halogen, hydroxy, C₁-C₄ alkoxy, cyano or C₁-C₄ alkyl;

R⁶ is H, hydroxy, amino, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₈ haloalkoxyalkyl,

C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl,

C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl,

C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkoxycarbonyl, C₄-C₁₀

cycloalkoxycarbonyl, C₂-C₈ alkylamino carbonyl, C₃-C₁₀

dialkylaminocarbonyl, C₄-C₁₀ cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆

10

15

20

25

30

35

alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹;

5 each R⁷ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₄–C₁₀ cycloalkylalkoxy, C₄–C₁₀ cycloalkylalkyl, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or G²; or R¹⁷ON=CR^{17a}–, (R¹⁸)₂C=NO–, (R¹⁹)₂NN=CR^{17a}–, (R¹⁸)₂C=NNR^{20a}–, R²⁰N=CR^{17a}–, (R¹⁸)₂C=N–, R¹⁷ON=CR^{17a}C(R^{23b})₂– or (R¹⁸)₂C=NOC(R^{24a})₂–, wherein the free bond projecting to the right indicates the connecting point to Q¹; or

30 two adjacent R⁷ are taken together along with the carbon atoms to which they are bonded to form a C₃–C₇ cycloalkyl ring;

each R¹⁰ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy,

C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyoxy, C₃–C₈ haloalkynyoxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₄–C₁₀ cycloalkylalkoxy, C₄–C₁₀ cycloalkylalkyl, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or G²; or R¹⁷ON=CR^{17a}–, (R¹⁸)₂C=NO–, (R¹⁹)₂NN=CR^{17a}–, (R¹⁸)₂C=NNR^{20a}–, R²⁰N=CR^{17a}–, (R¹⁸)₂C=N–, R¹⁷ON=CR^{17a}C(R^{23b})₂– or (R¹⁸)₂C=NOC(R^{24a})₂–, wherein the free bond projecting to the right indicates the connecting point to Q²; or

two adjacent R¹⁰ are taken together along with the carbon atoms to which they are bonded to form a C₃–C₇ cycloalkyl ring;

each R⁸ is independently H, cyano, C₂–C₃ alkylcarbonyl or C₂–C₃ haloalkylcarbonyl;

each R⁹ and R¹¹ is independently cyano, C₁–C₃ alkyl, C₂–C₃ alkenyl, C₂–C₃ alkynyl, C₃–C₆ cycloalkyl, C₂–C₃ alkoxyalkyl, C₁–C₃ alkoxy, C₂–C₃ alkylcarbonyl, C₂–C₃ alkoxy carbonyl, C₂–C₃ alkylaminoalkyl or C₃–C₄ dialkylaminoalkyl;

each R¹² is independently H, cyano, C₁–C₄ alkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, -(C=O)CH₃ or -(C=O)CF₃;

each G¹ is independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenoxy, phenylethynyl, phenylsulfonyl, phenylcarbonylalkyl, 2-, 3- or 4-pyridinyloxy or a 5- or 6-membered heteroaromatic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R¹³;

each G² is independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl, phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl, 2-, 3- or 4-pyridinyloxy or a 5- or 6-membered heteroaromatic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R¹⁴;

each R¹³ and R¹⁴ is independently halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH₂, -SO₂NH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₄-C₁₀ cycloalkyloxycarbonyl, C₅-C₁₂ cycloalkylalkyloxycarbonyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₈ alkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino, C₂-C₈ alkylcarbonylamino, C₁-C₆ alkylsulfonylamino, phenyl, pyridinyl or thienyl;

each R¹⁵ is independently halogen, cyano, hydroxy, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₂-C₄ alkoxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄ alkoxy carbonyl, C₃-C₆ cycloalkyl or C₄-C₈ cycloalkylalkyl; or two R¹⁵ are taken together with the carbon atom or atoms to which they are bonded to form a C₃-C₇ cycloalkyl ring;

each R¹⁶ is independently cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₂-C₄ alkylcarbonyl, C₂-C₄ alkoxy carbonyl or C₃-C₆ cycloalkyl;

each R¹⁷ is independently H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkyloxycarbonyl, C₄-C₁₀ cycloalkyloxycarbonyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₃-C₈ cycloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl or C₃-C₁₀ trialkylsilyl; or G¹;

each R^{17a} is independently H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio or C₃-C₁₀ trialkylsilyl; or G¹;

each R¹⁸ is independently H, hydroxy, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkyloxycarbonyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₃-C₈ cycloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl or C₃-C₁₀ trialkylsilyl; or G¹;

haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹; each R¹⁹ is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹; each R²⁰ is independently H, hydroxy, amino, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl or C₃–C₁₀ trialkylsilyl; or G¹; each R^{20a} is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₆ alkoxy or C₃–C₁₀ trialkylsilyl; or G¹; each R^{23b} is independently H, halogen, cyano, hydroxy, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl; each R^{24a} is independently H, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl; and

each u and v are independently 0, 1 or 2 in each instance of $S(=O)_u(=NR^8)_v$, provided that the sum of u and v is 0, 1 or 2;

provided when A is S and Q¹ is unsubstituted phenyl, Q² is other than unsubstituted phenyl.

5 2. The compound of Claim 1 wherein

A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NH}-$, $-\text{OCH}_2-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$ or $-\text{O}-$ wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1;

10 Q¹ is a phenyl ring substituted with up to 2 substituents independently selected from R⁷;

Q² is a phenyl ring substituted with up to 3 substituents independently selected from R¹⁰;

Y¹ and Y² are both O; and

15 J is $-\text{CR}^2\text{R}^3-$.

3. The compound of Claim 1 wherein

A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NH}-$, $-\text{OCH}_2-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$ or $-\text{O}-$ wherein the free bond projecting to the left indicates the connecting point of A to Q¹ and the free bond projecting to the right indicates the connecting point of A to the remainder of Formula 1;

20 Q¹ is a phenyl ring substituted with up to 2 substituents independently selected from R⁷;

Q² is a phenyl ring substituted with up to 3 substituents independently selected from R¹⁰;

25 Y¹ and Y² are both O; and

J is $-\text{CR}^2\text{R}^3-\text{CR}^{2a}\text{R}^{3a}-$.

4. The compound of Claim 2 wherein

A is $-\text{CH}_2-$;

30 R¹ is H, Me or Et;

R² is H;

R³ is H;

R⁴ is H;

R⁵ is H;

R⁶ is H;

35 R⁷ is independently is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈

nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyoxy, C₃–C₈ haloalkynyoxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

10 R¹⁰ is independently halogen, cyano, nitro, C₁–C₂ alkyl, C₁–C₃ haloalkyl or C₁–C₃ alkylsulfonyl.

5. The compound of Claim 3 wherein

15 A is -CH₂-;

R¹ is H, Me or Et;

R² is H;

R³ is H;

R^{2a} is H;

20 R^{3a} is H;

R⁴ is H;

R⁵ is H;

R⁶ is H;

R⁷ is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyoxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

25

30

35

R^{10} is independently halogen, cyano, nitro, C_1 – C_2 alkyl, C_1 – C_3 haloalkyl or C_1 – C_3 alkylsulfonyl.

6. The compound of Claim 4 wherein

each R^7 is independently halogen, cyano, C_1 – C_2 alkyl, C_1 – C_3 haloalkyl or C_1 – C_3 alkylsulfonyl; and

each R^{10} is independently halogen or C_1 – C_2 haloalkyl.

7. The compound of Claim 6 wherein

Q^1 is a phenyl ring substituted with 1 substituent independently selected from R^7 ;

Q^2 is a phenyl ring having 2 substituents selected from R^{10} and one of the said

10 substituents is at an ortho position and the other said substituent is at meta or para position.

8. The compound of Claim 6 wherein

Q^2 is a phenyl ring substituted with three substituents selected from R^{10} and the three substituents are at an ortho, meta and para positions of the phenyl ring.

9. The compound of Claim 1 wherein

A is selected from $-\text{ON}=\text{CH}-$, $-\text{ON}=\text{C}(\text{CH}_3)-$, $-\text{NHN}=\text{CH}-$, $-\text{NHN}=\text{C}(\text{CH}_3)-$, $-\text{N}=\text{CH}-$, $-\text{N}=\text{C}(\text{CH}_3)-$, $-\text{CH}=\text{NO}-$, $-\text{C}(\text{CH}_3)=\text{NO}-$, $-\text{CH}=\text{NNH}-$, $-\text{C}(\text{CH}_3)=\text{NNH}-$, $-\text{CH}=\text{N}-$, $-\text{C}(\text{CH}_3)=\text{N}-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2-$, $-\text{CF}_2-$, $-\text{C}(=\text{O})-$, $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CHCH}_2-$, $-\text{CH}_2\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCH}_2-$, $-\text{CH}_2\text{C}\equiv\text{C}-$, $-\text{CH}_2\text{CH}_2\text{O}-$, $-\text{CH}_2\text{O}-$, $-\text{O}-$, $-\text{OCH}_2\text{CH}_2-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{CH}_2\text{S}-$, $-\text{CH}_2\text{S}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{SCH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{NH}-$, $-\text{NH}-$, $-\text{NHCH}_2-$ and $-\text{NHCH}_2\text{CH}_2-$, wherein the bond projecting to the left is connected to the Q^1 moiety, and the bond projecting to the right is connected to the remainder of Formula 1;

25 Q^1 is a phenyl ring optionally substituted with 1 to 4 substituents independently selected from R^7 ; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members;

30 Q^2 is a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{10} ; or a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{11} on carbon atom ring members and selected from R^{11} on nitrogen atom ring members;

Y¹ and Y² are both O;

R¹ is H, hydroxy, amino, cyano, formyl, C₃–C₈ alkylcarbonylalkyl, -C(C₁–C₄ alkyl)=N-O(C₁–C₄ alkyl), -C(O)NH₂, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₆ cyanoalkyl, C₃–C₆ cycloalkyl, C₄–C₈

5 cycloalkylalkyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl or C₂–C₈ haloalkoxyalkyl;

R⁶ is H, hydroxy, amino, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl or C₂–C₈ haloalkoxyalkyl;

10 each R⁷ is independently halogen, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀

15 alkylcyclolalkyl, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, hydroxy, formyl, C₂–C₈ alkylcarbonyl, C₂–C₈ alkylcarbonyloxy, C₁–C₈

20 alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

each R¹⁰ is independently halogen, hydroxy, cyano, nitro, C₁–C₈ alkyl, C₂–C₈ cyanoalkyl, C₁–C₈ cyanoalkoxy, C₁–C₈ haloalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₁–C₈ nitroalkyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl or C₃–C₈ cycloalkyl.

10. The compound of Claim 1 selected from the group consisting of N-(2,3-difluorophenyl)-4-[(4-fluorophenyl)methyl]-2-oxo-3-pyrrolidinecarboxamide; and

30 4-[(3-chlorophenyl)methyl]-N-(2,3-difluorophenyl)-2-oxo-3-pyrrolidinecarboxamide.

11. A herbicidal composition comprising a compound of Claim 1 and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.

35 12. A herbicidal composition comprising a compound of Claim 1, at least one additional active ingredient selected from the group consisting of other herbicides

and herbicide safeners, and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.

13. A herbicidal mixture comprising (a) a compound of Claim 1, and (b) at least one additional active ingredient selected from (b1) photosystem II inhibitors, (b2)

5 acetohydroxy acid synthase (AHAS) inhibitors, (b3) acetyl-CoA carboxylase (ACCase) inhibitors, (b4) auxin mimics, (b5) 5-enol-pyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, (b6) photosystem I electron diverters, (b7)

10 protoporphyrinogen oxidase (PPO) inhibitors, (b8) glutamine synthetase (GS) inhibitors, (b9) very long chain fatty acid (VLCFA) elongase inhibitors, (b10) auxin

15 transport inhibitors, (b11) phytoene desaturase (PDS) inhibitors, (b12) 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors, (b13) homogentisate solenesyltransferase (HST) inhibitors, (b14) cellulose biosynthesis inhibitors, (b15) other herbicides including mitotic disruptors, organic arsenicals, asulam, bromobutide, cinmethylin, cumyluron, dazomet, difenzoquat, dymron, etobenzanid, flurenol, fosamine, fosamine-ammonium, hydantocidin, metam, methylidymron, oleic acid, oxaziclomefone, pelargonic acid and pyributicarb, and (b16) herbicide safeners; and salts of compounds of (b1) through (b16).

14. A method for controlling the growth of undesired vegetation comprising

20 contacting the vegetation or its environment with a herbicidally effective amount of a compound of Claim 1.